US20190216343A1 - Method and System for Controlling Electrical Conditions of Tissue - Google Patents

Method and System for Controlling Electrical Conditions of Tissue Download PDF

Info

Publication number
US20190216343A1
US20190216343A1 US16/224,641 US201816224641A US2019216343A1 US 20190216343 A1 US20190216343 A1 US 20190216343A1 US 201816224641 A US201816224641 A US 201816224641A US 2019216343 A1 US2019216343 A1 US 2019216343A1
Authority
US
United States
Prior art keywords
electrode
feedback
stimulus
amplifier
measurement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US16/224,641
Other versions
US11389098B2 (en
Inventor
Peter Scott Vallack Single
James Hamilton Laird-Wah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicta IPR Pty Ltd
National ICT Australia Ltd
Saluda Medical Pty Ltd
Original Assignee
Saluda Medical Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012904838A external-priority patent/AU2012904838A0/en
Application filed by Saluda Medical Pty Ltd filed Critical Saluda Medical Pty Ltd
Priority to US16/224,641 priority Critical patent/US11389098B2/en
Publication of US20190216343A1 publication Critical patent/US20190216343A1/en
Assigned to NATIONAL ICT AUSTRALIA LTD reassignment NATIONAL ICT AUSTRALIA LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SINGLE, Peter Scott Vallack, Wah, James Hamilton
Assigned to NICTA IPR PTY LTD reassignment NICTA IPR PTY LTD CONFIRMATION OF ASSIGNMENT Assignors: NATIONAL ICT AUSTRALIA LTD
Assigned to SALUDA MEDICAL PTY LTD reassignment SALUDA MEDICAL PTY LTD CONFIRMATION OF ASSIGNMENT Assignors: NICTA IPR PTY LTD
Priority to US17/664,568 priority patent/US11944439B2/en
Application granted granted Critical
Publication of US11389098B2 publication Critical patent/US11389098B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A61B5/04001
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/24Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/48Other medical applications
    • A61B5/4848Monitoring or testing the effects of treatment, e.g. of medication
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/68Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6846Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
    • A61B5/6847Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
    • A61B5/686Permanently implanted devices, e.g. pacemakers, other stimulators, biochips
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7203Signal processing specially adapted for physiological signals or for diagnostic purposes for noise prevention, reduction or removal
    • A61B5/7217Signal processing specially adapted for physiological signals or for diagnostic purposes for noise prevention, reduction or removal of noise originating from a therapeutic or surgical apparatus, e.g. from a pacemaker
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/36125Details of circuitry or electric components
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/36128Control systems
    • A61N1/36132Control systems using patient feedback
    • A61B5/04004
    • A61B5/0428
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/24Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/30Input circuits therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/40Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4029Detecting, measuring or recording for evaluating the nervous system for evaluating the peripheral nervous systems
    • A61B5/4041Evaluating nerves condition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7203Signal processing specially adapted for physiological signals or for diagnostic purposes for noise prevention, reduction or removal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7225Details of analog processing, e.g. isolation amplifier, gain or sensitivity adjustment, filtering, baseline or drift compensation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7228Signal modulation applied to the input signal sent to patient or subject; demodulation to recover the physiological signal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271Specific aspects of physiological measurement analysis
    • A61B5/7296Specific aspects of physiological measurement analysis for compensation of signal variation due to stress unintentionally induced in the patient, e.g. due to the stress of the medical environment or examination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/36128Control systems
    • A61N1/36135Control systems using physiological parameters
    • A61N1/36139Control systems using physiological parameters with automatic adjustment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/36128Control systems
    • A61N1/36146Control systems specified by the stimulation parameters

Definitions

  • the present invention relates to controlling the electrical conditions of tissue, for example for use in suppressing artefact to enable improved measurement of a response to a stimulus, such as measurement of a compound action potential by using one or more electrodes implanted proximal to a neural pathway.
  • Neuromodulation is used to treat a variety of disorders including chronic pain, Parkinson's disease, and migraine.
  • a neuromodulation system applies an electrical pulse to tissue in order to generate a therapeutic effect.
  • the electrical pulse is applied to the dorsal column (DC) of the spinal cord or dorsal root ganglion (DRG).
  • DC dorsal column
  • DRG dorsal root ganglion
  • Such a system typically comprises an implanted electrical pulse generator, and a power source such as a battery that may be rechargeable by transcutaneous inductive transfer.
  • An electrode array is connected to the pulse generator, and is positioned in the dorsal epidural space above the dorsal column.
  • An electrical pulse applied to the dorsal column by an electrode causes the depolarisation of neurons, and generation of propagating action potentials.
  • the fibres being stimulated in this way inhibit the transmission of pain from that segment in the spinal cord to the brain.
  • the DC is the target of the electrical stimulation, as it contains the afferent A ⁇ fibres of interest.
  • a ⁇ fibres mediate sensations of touch, vibration and pressure from the skin.
  • the prevailing view is that SCS stimulates only a small number of AP fibres in the DC.
  • the pain relief mechanisms of SCS are thought to include evoked antidromic activity of A ⁇ fibres having an inhibitory effect, and evoked orthodromic activity of A ⁇ fibres playing a role in pain suppression. It is also thought that SCS recruits A ⁇ nerve fibres primarily in the DC, with antidromic propagation of the evoked response from the DC into the dorsal horn thought to synapse to wide dynamic range neurons in an inhibitory manner.
  • Neuromodulation may also be used to stimulate efferent fibres, for example to induce motor functions.
  • the electrical stimulus generated in a neuromodulation system triggers a neural action potential which then has either an inhibitory or excitatory effect.
  • Inhibitory effects can be used to modulate an undesired process such as the transmission of pain, or to cause a desired effect such as the contraction of a muscle.
  • the action potentials generated among a large number of fibres sum to form a compound action potential (CAP).
  • the CAP is the sum of responses from a large number of single fibre action potentials.
  • the CAP recorded is the result of a large number of different fibres depolarising.
  • the propagation velocity is determined largely by the fibre diameter and for large myelinated fibres as found in the dorsal root entry zone (DREZ) and nearby dorsal column the velocity can be over 60 ms ⁇ 1 .
  • the CAP generated from the firing of a group of similar fibres is measured as a positive peak potential P 1 , then a negative peak N 1 , followed by a second positive peak P 2 . This is caused by the region of activation passing the recording electrode as the action potentials propagate along the individual fibres.
  • CAP neuromodulation
  • Electrode artefact usually results from the stimulus, and manifests as a decaying output of several millivolts throughout the time that the CAP occurs, presenting a significant obstacle to isolating the CAP of interest.
  • Some neuromodulators use monophasic pulses and have capacitors to ensure there is no DC flow to the tissue.
  • a number of approaches have been proposed for recording a CAP. King (U.S. Pat. No. 5,913,882) measures the spinal cord potential (SCP) using electrodes which are physically spaced apart from the stimulus site. To avoid amplifier saturation during the stimulus artefact period, recording starts at least 1-2.5 ms after the stimulus. At typical neural conduction velocities, this requires that the measurement electrodes be spaced around 10 cm or more away from the stimulus site, which is undesirable as the measurement then necessarily occurs in a different spinal segment and may be of reduced amplitude.
  • SCP spinal cord potential
  • Nygard (U.S. Pat. No. 5,785,651) measures the evoked CAP upon an auditory nerve in the cochlea, and aims to deal with artefacts by a sequence which comprises: (1) equilibrating electrodes by short circuiting stimulus electrodes and a sense electrode to each other; (2) applying a stimulus via the stimulus electrodes, with the sense electrode being open circuited from both the stimulus electrodes and from the measurement circuitry; (3) a delay, in which the stimulus electrodes are switched to open circuit and the sense electrode remains open circuited; and (4) measuring, by switching the sense electrode into the measurement circuitry.
  • Nygard also teaches a method of nulling the amplifier following the stimulus. This sets a bias point for the amplifier during the period following stimulus, when the electrode is not in equilibrium. As the bias point is reset each cycle, it is susceptible to noise.
  • the Nygard measurement amplifier is a differentiator during the nulling phase which makes it susceptible to pickup from noise and input transients when a non-ideal amplifier with finite gain and bandwidth
  • Daly (US Patent Application No. 2007/0225767) utilizes a biphasic stimulus plus a third phase “compensatory” stimulus which is refined via feedback to counter stimulus artefact.
  • Daly's focus is the cochlea.
  • Daly's measurement sequence comprises (1) a quiescent phase where stimulus and sense electrodes are switched to Vdd; (2) applying the stimulus and then the compensatory phase, while the sense electrodes are open circuited from both the stimulus electrodes and from the measurement circuitry; (3) a load settling phase of about 1 ⁇ s in which the stimulus electrodes and sense electrodes are shorted to Vdd; and (4) measurement, with stimulus electrodes open circuited from Vdd and from the current source, and with sense electrodes switched to the measurement circuitry.
  • Evoked responses are less difficult to detect when they appear later in time than the artefact, or when the signal-to-noise ratio is sufficiently high.
  • the artefact is often restricted to a time of 1-2 ms after the stimulus and so, provided the neural response is detected after this time window, data can be obtained. This is the case in surgical monitoring where there are large distances between the stimulating and recording electrodes so that the propagation time from the stimulus site to the recording electrodes exceeds 2 ms.
  • cochlear implants use small stimulation currents relative to the tens of mA sometimes required for SCS, and thus measured signals in cochlear systems present a relatively lower artefact.
  • high stimulation currents and close proximity between electrodes are required.
  • the measurement process must overcome artefact directly, in contrast to existing “surgical monitoring” techniques involving measurement electrode(s) which are relatively distant from the stimulus electrode(s).
  • the present invention provides a method for controlling electrical conditions of tissue, the method comprising:
  • the present invention provides a method for measuring a neural response to a stimulus, the method comprising:
  • the present invention provides an implantable device for controlling electrical conditions of tissue, the device comprising:
  • the device of the third aspect may be further configured for measuring a neural response to a stimulus, and may further comprise: one or more nominal stimulus electrodes; one or more nominal sense electrodes; a stimulus source for providing a stimulus to be delivered from the one or more stimulus electrodes to neural tissue; measurement circuitry for amplifying a neural signal sensed at the one or more sense electrodes; and a control unit configured to apply an electrical stimulus to the neural tissue from the stimulus electrode and obtain a measurement of a neural response from the measurement electrode.
  • the feedback amplifier may be disconnected during application of a neural stimulus by disconnecting the feedback sense electrode from the feedback amplifier and/or by disconnecting an output of the feedback amplifier from the compensation electrode.
  • the feedback amplifier may operate and be in connection with the feedback sense electrode and compensation electrode.
  • the feedback sense electrode and the measurement electrode are located outside the dipole formed by the stimulus electrode and the compensating electrode.
  • the operation of the feedback amplifier acts to spatially shield the measurement electrode from the stimulus field, noting that the voltage at points between the poles of a dipole is comparable to the voltage on the electrodes, whereas outside the dipole the voltage drops with the square of distance.
  • Preferred embodiments of the invention may thus reduce artefact by reducing interaction between the stimulus and the measurement recording via a measurement amplifier input capacitance.
  • Some embodiments of the invention may utilise a blanking circuit for blanking the measurement amplifier during and/or close in time to the application of a stimulus.
  • alternative embodiments may utilise an unblanked measurement amplifier, which connects a measurement electrode to an analog-to-digital circuit, significantly reducing complexity in the measurement signal chain.
  • the desired electrical value may be zero voltage, i.e. electrical ground.
  • the electrical ground may be referenced to a patient ground electrode distal from the array such as a device body electrode, or to a device ground. Driving the feedback signal to ground will thus act to counteract any non-zero stimulus artefact produced by application of the stimulus.
  • a non-zero voltage may in some circumstances be desired in the tissue and the feedback amplifier may thus be referenced to a non-zero electrical value in such embodiments.
  • the electrodes are preferably part of a single electrode array, and are physically substantially identical whereby any electrode of the array may serve as any one of the nominal electrodes at a given time.
  • the electrodes may be separately formed, and not in a single array, while being individually positioned proximal to the tissue of interest.
  • the feedback sense electrode, compensation electrode, stimulus electrode and sense electrode are selected from an implanted electrode array.
  • the electrode array may for example comprise a linear array of electrodes arranged in a single column along the array.
  • the electrode array may comprise a two dimensional array having two or more columns of electrodes arranged along the array.
  • each electrode of the electrode array is provided with an associated measurement amplifier, to avoid the need to switch the sense electrode(s) to a shared measurement amplifier, as such switching can add to measurement artefact.
  • Providing a dedicated measurement amplifier for each sense electrode is further advantageous in permitting recordings to be obtained from multiple sense electrodes simultaneously.
  • the measurement may be a single-ended measurement obtained by passing a signal from a single sense electrode to a single-ended amplifier.
  • the measurement may be a differential measurement obtained by passing signals from two measurement electrodes to a differential amplifier.
  • a single stimulus electrode may apply monopolar stimulus referenced to a distal reference point such as an implant case body, alternatively two stimulus electrodes may be used to apply bipolar stimuli, or three stimulus electrodes may be used to apply a tripolar stimulus for example using on stimulus electrode as a cathode and two stimulus electrodes as anodes, and vice versa.
  • the stimulus may be monophasic, biphasic, or otherwise.
  • Embodiments of the invention may prove beneficial in obtaining a CAP measurement which has lower dynamic range and simpler morphology as compared to systems more susceptible to artefact. Such embodiments of the present invention may thus reduce the dynamic range requirements of implanted amplifiers, and may avoid or reduce the complexity of signal processing systems for feature extraction, simplifying and miniaturizing an implanted integrated circuit. Such embodiments may thus be particularly applicable for an automated implanted evoked response feedback system for stimulus control.
  • the present invention provides a computer program product comprising computer program code means to make an implanted processor execute a procedure for controlling electrical conditions of neural tissue, the computer program product comprising computer program code means for carrying out the method of the first or second aspect.
  • the present invention provides a computer readable storage medium, excluding signals, loaded with computer program code means to make an implanted processor execute a procedure for controlling electrical conditions of neural tissue, the computer readable storage medium loaded with computer program code means for carrying out the method of the first or second aspect.
  • the present invention recognises that when considering spinal cord stimulation, obtaining information about the activity within the spinal segment where stimulation is occurring is highly desirable. Observing the activity and extent of propagation both above (rostrally of) and below (caudally of) the level of stimulation is also highly desirable.
  • the present invention recognises that in order to record the evoked activity within the same spinal segment as the stimulus requires an evoked potential recording system which is capable of recording an SCP within approximately 3 cm of its source, i.e. within approximately 0.3 ms of the stimulus, and further recognises that in order to record the evoked activity using the same electrode array as applied the stimulus requires an evoked potential recording system which is capable of recording an SCP within approximately 7 cm of its source, i.e. within approximately 0.7 ms of the stimulus.
  • the method of the present invention may be applied to measurement of other bioelectrical signals, such as muscle potentials.
  • the method of the present invention may be applicable to any measurement of any voltage within tissue during or after stimulation, and where the stimulation may obscure the voltage being measured.
  • Such situations include the measurement of evoked spinal cord potentials, potentials evoked local to an electrode during deep brain stimulation (DBS), the measurement of EEGs during deep brain stimulation (where the source of the potential is distant from the stimulating electrodes), the measurement of signals in the heart (ECGs) by a pacemaker, the measurement of voltages in stimulated muscles (EMGs), and the measurement of EMGs triggered by the stimulation of distant and controlling nervous tissue.
  • FIG. 1 illustrates an implantable device suitable for implementing the present invention
  • FIG. 2 illustrates currents and voltages which can contribute to SCP measurements
  • FIG. 3 illustrates the equivalent circuit of a typical system for applying a neural stimulus and attempting to measure a neural response
  • FIG. 4 is an equivalent circuit modelling the tissue/electrode interface and electrode loading
  • FIG. 5 a illustrates a virtual ground system configuration, with double-ended measurement, in accordance with one embodiment of the invention
  • FIG. 5 b illustrates a virtual ground system configuration, with single-ended measurement, in accordance with another embodiment of the invention
  • FIG. 5 c is a model of the embodiment of FIG. 5 b
  • FIG. 5 d is an equivalent circuit of the model of FIG. 5 c;
  • FIG. 6 is a system schematic illustrating multiplexing of virtual ground functionalities across multiple electrodes
  • FIG. 7 a illustrates an equivalent circuit of the virtual GND embodiment of FIG. 6 ;
  • FIG. 7 b illustrates an active ground “bridge” driver in accordance with an embodiment of the invention
  • FIG. 8 a illustrates the operation of the embodiment of FIG. 6 when the virtual ground function is disabled
  • FIGS. 8 b and 8 c show the operation of the circuit of FIG. 6 when the virtual ground function is activated, when experimentally demonstrated on a bench using a saline bath;
  • FIG. 9 a illustrates the operation of the embodiment of FIG. 6 when the virtual ground function is disabled, with amplifier blanking
  • FIG. 9 b illustrates the step response of the embodiment of FIG. 6 when the virtual ground function is enabled, with amplifier blanking;
  • FIG. 10 a illustrates the performance of the embodiment of FIG. 6 when the virtual ground function is disabled, with amplifier blanking and sinusoid injection
  • FIG. 10 b illustrates the step response of the embodiment of FIG. 6 when the virtual ground function is enabled, with amplifier blanking and sinusoid injection
  • FIG. 11 a plots the measurements from an electrode array in response to a stimulus delivered by the array to a sheep dorsal column, while FIG. 11 b is a superimposed plot of similar data, demonstrating timing of respective signal features;
  • FIG. 12 illustrates an alternative embodiment intended for ASIC implementation
  • FIG. 13 illustrates another embodiment intended for ASIC implementation
  • FIG. 14 illustrates yet another embodiment intended for ASIC implementation.
  • FIG. 1 illustrates an implantable device 100 suitable for implementing the present invention.
  • Device 100 comprises an implanted control unit 110 , which controls application of a sequence of neural stimuli.
  • the unit 110 is also configured to control a measurement process for obtaining a measurement of a neural response evoked by a single stimulus delivered by one or more of the electrodes 122 .
  • Device 100 further comprises an electrode array 120 consisting of a three by eight array of electrodes 122 , each of which may be selectively used as the stimulus electrode, sense electrode, compensation electrode or sense electrode.
  • FIG. 2 shows the currents and voltages that contribute to spinal cord potential (SCP) measurements in a typical system of the type shown in FIG. 3 .
  • These signals include the stimulus current 202 applied by two stimulus electrodes, which is a charge-balanced biphasic pulse to avoid net charge transfer to or from the tissue and to provide low artefact.
  • Alternative embodiments may instead use three electrodes to apply a tripolar charge balanced stimulus for example where a central electrode.
  • the stimulus currents 202 used to provide paraesthesia and pain relief typically consist of pulses in the range of 3-30 mA amplitude, with pulse width typically in the range of 100-400 ⁇ s, or alternatively may be paraesthesia-free such as neuro or escalator style stimuli.
  • the stimuli can comprise monophasic or biphasic pulses.
  • the stimulus 202 induces a voltage on adjacent electrodes, referred to as stimulus crosstalk 204 .
  • the stimuli 202 are SCP stimuli they typically induce a voltage 204 in the range of about 1-5 V on a SCP sense electrode.
  • the stimulus 202 also induces electrode artefact.
  • the mechanism of artefact production can be considered as follows.
  • the stimulus crosstalk can be modelled as a voltage, with an equivalent output impedance. In a human spinal cord, this impedance is typically around 500 ohms per electrode, but will be larger or smaller in different applications. This resistance has little effect in the circuit, but is included for completeness.
  • the stimulus crosstalk drives the measurement amplifiers through the electrode/tissue interface. This interface is shown in FIG. 4 as a set of series capacitance/resistance pairs, modelling a component referred to in the literature as a “Warburg element”.
  • the RC pairs model the complex diffusion behaviour at the electrode surface, and have time constants from micro-seconds to seconds.
  • the cables from the electrode to the amplifier add capacitance which loads the electrode, along with the resistive input impedance of the amplifier itself.
  • Typical loading would be 200 pF of capacitance and 1 megohms of resistance. Following this is an ideal amplifier in this equivalent circuit of FIG. 4 .
  • the electrode artefact is the response of the electrode/tissue interface, when driven by the stimulus crosstalk and loaded by the capacitance and resistance at the amplifier input. It can be observed, either with a circuit simulator or in a laboratory. It can also be observed that the sign of the artefact is opposite for capacitive and resistive loading. Electrical artefact usually also arises from the behaviour of the amplifier circuitry in response to these particular circumstances.
  • an appropriate electrical stimulus 202 will induce nerves to fire, and thereby produces an evoked neural response 206 .
  • the neural response 206 can have two major components: a fast response lasting ⁇ 2 ms and a slow response lasting ⁇ 15 ms. The slow response only appears at stimulation amplitudes which are larger than the minimum stimulus required to elicit a fast response.
  • Many therapeutic stimuli paradigms seek to evoke fast responses only, and to avoid evoking any slow response.
  • the neural response of interest for neural response measurements concludes within about 2 ms.
  • the amplitude of the evoked response seen by epidural electrodes is typically no more than hundreds of microvolts, but in some clinical situations can be only tens of microvolts.
  • a measurement amplifier used to measure the evoked response does not have infinite bandwidth, and will normally have infinite impulse response filter poles, and so the stimulus crosstalk 204 will produce an output 208 during the evoked response 206 , this output being referred to as electrical artefact.
  • Electrical artefact can be in the hundreds of millivolts as compared to a SCP of interest in the tens of microvolts. Electrical artefact can however be somewhat reduced by suitable choice of a high-pass filter pole frequency.
  • the measurement amplifier output 210 will therefore contain the sum of these various contributions 202 - 208 .
  • Separating the evoked response of interest ( 206 ) from the artefacts 204 and 208 is a significant technical challenge. For example, to resolve a 10 ⁇ V SCP with 1 ⁇ V resolution, and have at the input a 5V stimulus, requires an amplifier with a dynamic range of 134 dB. As the response can overlap the stimulus this represents a difficult challenge of amplifier design.
  • FIG. 5 a illustrates a neural stimulus and response system providing differential neural measurements and using a shared electrode for measurement and for feedback sense.
  • Alternative embodiments could use two separate electrodes for measurements and feedback sense, respectively.
  • FIG. 5 b illustrates a configuration of device 100 for controlling electrical conditions of neural tissue in accordance with another embodiment of the present invention, providing single ended neural measurements.
  • the device has a current source 502 which drives current into tissue via stimulus electrode 504 in order to stimulate the neural tissue and evoke a neural response.
  • a feedback sense electrode 506 , compensation electrode 508 and measurement electrode 510 are also provided.
  • the electrodes 504 - 510 are positioned proximal to neural tissue to make electrical contact with the tissue.
  • a feedback amplifier 512 is referenced to ground 514 and takes as an input a feedback signal from the feedback sense electrode 506 .
  • An output of the feedback amplifier 512 is connected to the compensation electrode 508 such that the feedback amplifier 512 is configured to drive the tissue via the compensation electrode 508 in a feedback arrangement which seeks to drive the feedback signal to ground. This mechanism will thus operate to quash stimulus artefact at the tissue electrode interface, improving measurement conditions for neural response measurement circuitry 516 .
  • the adjacent stimulus, compensation, feedback sense and measurement electrodes in contact with resistive tissue can be modelled as respective contacts each connected to a tissue rail by a respective resistance R 1 , R 2 , R 3 and R 4 .
  • FIG. 5 d An equivalent circuit of FIG. 5 c is shown in FIG. 5 d .
  • Stimulus and stimulus artefact occurring upon the stimulus electrode creates a current I through R 1 .
  • Feedback amplifier 512 operates to maintain zero current at each amplifier input, and also operates to maintain the voltage at each input to be identical. Therefore in the configuration of FIGS. 5 a - d , the voltage at each amplifier input is zero, because the positive input is referenced to ground.
  • current through R 3 is forced to zero, being the same as the input current to the amplifier 312 . This ensures that there is no voltage differential across R 3 , and that the tissue node must therefore be forced to ground, in this model. This effect is referred to herein as providing a virtual ground.
  • the voltage caused by the current stimulus travels at the speed of light in the tissue medium, whereas an evoked action potential in the neural tissue travels at around 60 m/s.
  • the feedback sense electrode is subject to (or senses) the evoked response it will cancel the stimulus crosstalk in the tissue, but due to the larger propagation delay, the voltages produced by the evoked response at different electrodes (such as the measurement electrodes) will differ, and can be recorded. It will simply be the voltage that would otherwise by recorded as the difference between the measurement electrode and the feedback sense electrode.
  • the sense electrode can be placed elsewhere in the tissue further from the stimulus electrode(s), and substantially no cancellation of the evoked response will then occur, although the electrode will be subject to other electrical signals in the body from muscles, and other nerve bundles. This might be the situation when the sense electrode is on the body of an implant, with the stimulating electrodes on a lead.
  • FIG. 6 is a system schematic illustrating multiplexing of virtual ground functionalities across multiple electrodes, applicable to the embodiment of FIG. 5 a or FIG. 5 b .
  • This shows the buffer at the output of the reference MUX.
  • a set of electrodes is connected to a current source and a set of amplifiers.
  • the “current source MUX” allows the stimulus current to be directed to any electrode.
  • the “Ground MUX” allows any electrode to be chosen as the second of the pair of stimulating electrodes.
  • Switches “Std” and “VG” allow the circuit to selectively provide conventional stimulation, or stimulation according to this invention.
  • a third multiplexor selects the electrode to be used as the reference point (feedback sense electrode). Once the electrode configuration has been chosen, the circuit operates according to FIGS. 5 a - d .
  • Each of the N electrodes of the array of FIG. 6 may thus, at any given time, nominally serve as any one of the stimulus, sense or measurement electrode.
  • the circuit of FIG. 6 may alternatively be modified such that the reference voltage passed to the virtual ground feedback amplifier is a combination of the voltages on the measurement electrodes, e.g. the average of two or more electrode voltages.
  • the virtual ground circuit of the embodiment of FIG. 5 b provides for the stimulus electrode 504 to be driven by a current source.
  • An op-amp circuit 512 and compensating electrode 508 provides a feedback loop holding the tissue voltage, as measured at a sense electrode 510 , to 0 V.
  • the voltage on the compensating electrode 508 is identical in amplitude but of opposite polarity to the voltage on the stimulating electrode 504 . This ideally leaves the potential on a measurement electrode 510 unchanged by the stimulation and thus significantly improves conditions for measurement of an evoked response with reduced artefact.
  • the components making up the virtual ground circuit are spread throughout the device 100 , having components in the reference multiplexer (Ref. MUX). As shown in FIG. 6 , an electrode is wired to the inverting input multiplexer. This includes a buffer to drive the capacitance on the inputs of the array of amplifiers, and the virtual ground amplifier. These components, their parasitics, and the capacitance of the wiring on the circuit boards from which the system is made must be considered in order to design a stable circuit.
  • FIG. 7 a illustrates the actual circuit used for the amplifier in the reference multiplexer (“Ref. MUX”) of FIG. 6 , in the preferred embodiment of the virtual ground circuit.
  • the reference signal selected by the MUX is buffered before it is passed to the amplifier negative inputs, and the virtual ground circuit.
  • the buffer uses a current feedback amplifier, because this amplifier is inside the virtual ground feedback loop and this amplifier introduces less phase shift than a voltage feedback device. This has been used both for experimental verification in a saline bath (from which the attached figures were obtained) and in a human subject.
  • the virtual ground circuit of this embodiment includes an inverting amplifier and a high-speed buffer.
  • the op-amp alone does not have the current sourcing capability to drive the current available from the current sources, which can deliver up to 50 mA.
  • the 470 p capacitor provides dominant pole compensation to the loop.
  • the switches are paralleled to provide low impedance paths, and match the switch configuration of FIG. 6 .
  • the FETs Q 902 and Q 903 in FIG. 7 b from the input to the supplies, provide electrostatic discharge (ESD) protection.
  • ESD electrostatic discharge
  • the capacitor C 900 and pulldown resistor R 901 set the DC bias point for the loop.
  • FIG. 8 a illustrates the problem of stimulus crosstalk when the virtual ground function is disabled.
  • Trace 801 is from Electrode 1 (stimulus electrode)
  • trace 804 is from Electrode 2 (ground electrode)
  • trace 802 is from Electrode 4 (first measurement electrode)
  • trace 803 is from Electrode 5 (second measurement electrode).
  • FIGS. 8 b and 8 c show the behaviour of the circuit of FIG. 6 when the virtual ground function is activated, when experimentally implemented on a bench using an actual saline bath.
  • FIGS. 8 b and 8 c show the response to a 10 mA biphasic pulse stimulus in 1/10 PBS (phosphate buffered saline).
  • PBS phosphate buffered saline
  • FIG. 9 a shows artefact with virtual ground disabled, and in particular shows the behaviour of the circuit of FIG. 6 when the virtual ground function is deactivated, when experimentally implemented on a bench using an actual saline bath.
  • FIG. 9 shows the measured voltages on two measurement electrodes, with a peak artefact of around 400 uV.
  • FIG. 9 b shows the amplifier outputs with virtual ground enabled, but otherwise identical stimulation as produced FIG. 9 a .
  • artefact is about 100 uV, or smaller by about 75%.
  • FIG. 10 a shows the amplifier output for the same experiment as FIG. 9 a , but with a 50 uV pp sinusoidal signal injected in series with electrode 4 , to give an idea of how an evoked response would superimpose upon the artefact.
  • the sinusoidal signal cannot be easily seen before about 1.5 ms, i.e. the first 1 ms of measurement time is obscured by the artefact.
  • FIG. 10 b is for the same experiment as FIG. 10 a but with virtual ground enabled.
  • the sinusoidal signal can be seen distinct from the artefact from around 0.75 ms, or about 750 us (80%) earlier than for FIG. 10 a relative to the unblanking time.
  • FIG. 11 a shows the evoked response in a sheep dorsal column.
  • FIG. 11 a plots the measurements obtained simultaneously from 22 electrodes of a 24 electrode array in response to a stimulus delivered by two adjacent electrodes positioned centrally in the array.
  • evoked responses propagate simultaneously both caudally and rostrally from the central stimulus site.
  • the current required to evoke such a response in a sheep is much lower than in humans, and the evoked response signals are higher, so artefact is less of a problem.
  • the sheep signals are similar to the human case.
  • FIG. 11 a the amplifiers are unblanked at approximately 0.75 msec and the response finishes within another 0.75 ms.
  • FIG. 11 b is a superimposed plot of similar data, demonstrating timing of respective signal features when measuring on multiple electrodes at increasing distance from the stimulus site.
  • FIGS. 11 a and 11 b illustrate the importance of reducing artefact during the period immediately after stimulation.
  • a first mode of operation in accordance with some embodiments of the invention, at the end of stimulation the stimulation electrodes are both disconnected.
  • the bath (or subject) is floating at this point, as there is no connection between the bath and the circuit ground. Since the amplifiers are all differential, taking the difference between the reference electrode and the other epidural electrodes will compensate for any change in voltage.
  • This mode of operation reflects the logic that other choices of which electrode to ground seem likely to worsen artefact: connecting a stimulation electrode will cause the bath potential to change as the electrode voltage settles; connecting an epidural electrode to GND might put a transient on it which would be seen on all the channels.
  • the VG circuit In a second mode of operation of other embodiments of the invention, the VG circuit remains active after the stimulation, which makes the bioelectrical situation quite different.
  • the voltage on the compensation electrode will change as the electrode potentials settle, but the VG loop will compensate for this so it will not affect the bath potential.
  • the VG circuit can hold the bath at a fixed voltage—GND.
  • the VG circuit will attempt to keep the epidural space at a static voltage, namely GND.
  • the present invention is implemented in an application-specific integrated circuit (ASIC).
  • ASIC application-specific integrated circuit
  • the primary difference that is encountered in an ASIC implementation is that whereas most PCB amplifiers and components are intended for split supply operation, most ASIC designs, especially one intended for implantable operation, will operate from a single supply. Also, in an ASIC, the desire to produce a low-cost design is increased, as an ASIC implementation would be preferable for commercial exploitation.
  • FIG. 12 shows a design intended for ASIC operation.
  • the design uses separate current sources to provide anodic and cathodic current. These are connected to an electrode array. They also electrodes to be arbitrarily connected to the output and input of the virtual ground amplifier.
  • the point “Vgref” provides the bias point for the amplifier; this would typically be half the power supply. In this case the power supply is called “VDDH”, indicating it is a high-voltage supply suitable for tissue stimulation.
  • the virtual ground amplifier provides the entire current for the second of the two stimulating electrodes. To create the ASIC implementation some changes were required.
  • the amplifier output provides the entire opposite current to that of the output of the current driver. This requires an amplifier with a considerable output drive, for example if the current source can drive 50 mA, so must the amplifier. An amplifier with this current drive, stable in a feedback loop, and with the required bandwidth can be difficult to obtain, although they are available.
  • a problem in an ASIC implementation is to provide the virtual ground amplifier with sufficient current capability to balance the current source; this takes considerable silicon area which incurs cost.
  • the present embodiment thus uses the circuit of FIG. 13 , suitable for integrated circuit implementation.
  • This implementation requires the use of matched positive and negative current drivers. It also operates from a single supply, simplifying the system implementation.
  • the feedback loop holds the tissue voltage at a stable voltage—the midpoint of the two supplies.
  • the amplifier only has to source or sink a current equal to the mismatch between the two amplifiers, denoted dl in FIG. 13 . Since the current source has a high output impedance, the load seen by the amplifier is unchanged as compared to the case of FIG. 5 a where the amplifier provides all the drive, however the amplifier no longer has to provide high current. In a case where the current sources match to 10%, a 0.1 reduction in capability is achieved.
  • FIG. 14 illustrates yet another embodiment, in which the amplifier is connected as a unity gain buffer. It is noted that this proposal may be integrated into the design of Australian Provisional Patent Application No. 2012904838.

Abstract

An implantable device for controlling electrical conditions of body tissue. A feedback sense electrode and a compensation electrode are positioned proximal to the tissue to make electrical contact with the tissue. A feedback amplifier is referenced to ground, and takes as an input a feedback signal from the feedback sense electrode. The output of the feedback amplifier is connected to the compensation electrode. The feedback amplifier thus drives the neural tissue via the compensation electrode in a feedback arrangement which seeks to drive the feedback signal to ground, or other desired electrical value.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. patent application Ser. No. 14/440,873, filed May 5, 2015, which is the National Stage of International Application No. PCT/AU2013/001279 filed Nov. 6, 2013, which claims the benefit of Australian Provisional Patent Application No. 2012904836 filed Nov. 6, 2012, and Australian Provisional Patent Application No. 2012904838 filed Nov. 6, 2012, which are incorporated herein by reference.
  • TECHNICAL FIELD
  • The present invention relates to controlling the electrical conditions of tissue, for example for use in suppressing artefact to enable improved measurement of a response to a stimulus, such as measurement of a compound action potential by using one or more electrodes implanted proximal to a neural pathway.
  • BACKGROUND OF THE INVENTION
  • Neuromodulation is used to treat a variety of disorders including chronic pain, Parkinson's disease, and migraine. A neuromodulation system applies an electrical pulse to tissue in order to generate a therapeutic effect. When used to relieve chronic pain, the electrical pulse is applied to the dorsal column (DC) of the spinal cord or dorsal root ganglion (DRG). Such a system typically comprises an implanted electrical pulse generator, and a power source such as a battery that may be rechargeable by transcutaneous inductive transfer. An electrode array is connected to the pulse generator, and is positioned in the dorsal epidural space above the dorsal column. An electrical pulse applied to the dorsal column by an electrode causes the depolarisation of neurons, and generation of propagating action potentials. The fibres being stimulated in this way inhibit the transmission of pain from that segment in the spinal cord to the brain.
  • While the clinical effect of spinal cord stimulation (SCS) is well established, the precise mechanisms involved are poorly understood. The DC is the target of the electrical stimulation, as it contains the afferent Aβ fibres of interest. Aβ fibres mediate sensations of touch, vibration and pressure from the skin. The prevailing view is that SCS stimulates only a small number of AP fibres in the DC. The pain relief mechanisms of SCS are thought to include evoked antidromic activity of Aβ fibres having an inhibitory effect, and evoked orthodromic activity of Aβ fibres playing a role in pain suppression. It is also thought that SCS recruits Aβ nerve fibres primarily in the DC, with antidromic propagation of the evoked response from the DC into the dorsal horn thought to synapse to wide dynamic range neurons in an inhibitory manner.
  • Neuromodulation may also be used to stimulate efferent fibres, for example to induce motor functions. In general, the electrical stimulus generated in a neuromodulation system triggers a neural action potential which then has either an inhibitory or excitatory effect. Inhibitory effects can be used to modulate an undesired process such as the transmission of pain, or to cause a desired effect such as the contraction of a muscle.
  • The action potentials generated among a large number of fibres sum to form a compound action potential (CAP). The CAP is the sum of responses from a large number of single fibre action potentials. The CAP recorded is the result of a large number of different fibres depolarising. The propagation velocity is determined largely by the fibre diameter and for large myelinated fibres as found in the dorsal root entry zone (DREZ) and nearby dorsal column the velocity can be over 60 ms−1. The CAP generated from the firing of a group of similar fibres is measured as a positive peak potential P1, then a negative peak N1, followed by a second positive peak P2. This is caused by the region of activation passing the recording electrode as the action potentials propagate along the individual fibres.
  • To better understand the effects of neuromodulation and/or other neural stimuli, it is desirable to record a CAP resulting from the stimulus. However, this can be a difficult task as an observed CAP signal will typically have a maximum amplitude in the range of microvolts, whereas a stimulus applied to evoke the CAP is typically several volts. Electrode artefact usually results from the stimulus, and manifests as a decaying output of several millivolts throughout the time that the CAP occurs, presenting a significant obstacle to isolating the CAP of interest. Some neuromodulators use monophasic pulses and have capacitors to ensure there is no DC flow to the tissue. In such a design, current flows through the electrodes at all times, either stimulation current or equilibration current, hindering spinal cord potential (SCP) measurement attempts. The capacitor recovers charge at the highest rate immediately after the stimulus, undesirably causing greatest artefact at the same time that the evoked response occurs.
  • To resolve a 10 uV SCP with 1 uV resolution in the presence of an input 5V stimulus, for example, requires an amplifier with a dynamic range of 134 dB, which is impractical in implant systems. As the neural response can be contemporaneous with the stimulus and/or the stimulus artefact, CAP measurements present a difficult challenge of amplifier design. In practice, many non-ideal aspects of a circuit lead to artefact, and as these mostly have a decaying exponential appearance that can be of positive or negative polarity, their identification and elimination can be laborious.
  • A number of approaches have been proposed for recording a CAP. King (U.S. Pat. No. 5,913,882) measures the spinal cord potential (SCP) using electrodes which are physically spaced apart from the stimulus site. To avoid amplifier saturation during the stimulus artefact period, recording starts at least 1-2.5 ms after the stimulus. At typical neural conduction velocities, this requires that the measurement electrodes be spaced around 10 cm or more away from the stimulus site, which is undesirable as the measurement then necessarily occurs in a different spinal segment and may be of reduced amplitude.
  • Nygard (U.S. Pat. No. 5,785,651) measures the evoked CAP upon an auditory nerve in the cochlea, and aims to deal with artefacts by a sequence which comprises: (1) equilibrating electrodes by short circuiting stimulus electrodes and a sense electrode to each other; (2) applying a stimulus via the stimulus electrodes, with the sense electrode being open circuited from both the stimulus electrodes and from the measurement circuitry; (3) a delay, in which the stimulus electrodes are switched to open circuit and the sense electrode remains open circuited; and (4) measuring, by switching the sense electrode into the measurement circuitry. Nygard also teaches a method of nulling the amplifier following the stimulus. This sets a bias point for the amplifier during the period following stimulus, when the electrode is not in equilibrium. As the bias point is reset each cycle, it is susceptible to noise. The Nygard measurement amplifier is a differentiator during the nulling phase which makes it susceptible to pickup from noise and input transients when a non-ideal amplifier with finite gain and bandwidth is used for implementation.
  • Daly (US Patent Application No. 2007/0225767) utilizes a biphasic stimulus plus a third phase “compensatory” stimulus which is refined via feedback to counter stimulus artefact. As for Nygard, Daly's focus is the cochlea. Daly's measurement sequence comprises (1) a quiescent phase where stimulus and sense electrodes are switched to Vdd; (2) applying the stimulus and then the compensatory phase, while the sense electrodes are open circuited from both the stimulus electrodes and from the measurement circuitry; (3) a load settling phase of about 1 μs in which the stimulus electrodes and sense electrodes are shorted to Vdd; and (4) measurement, with stimulus electrodes open circuited from Vdd and from the current source, and with sense electrodes switched to the measurement circuitry. However a 1 μs load settling period is too short for equilibration of electrodes which typically have a time constant of around 100 μs. Further, connecting the sense electrodes to Vdd pushes charge onto the sense electrodes, exacerbating the very problem the circuit is designed to address.
  • Evoked responses are less difficult to detect when they appear later in time than the artefact, or when the signal-to-noise ratio is sufficiently high. The artefact is often restricted to a time of 1-2 ms after the stimulus and so, provided the neural response is detected after this time window, data can be obtained. This is the case in surgical monitoring where there are large distances between the stimulating and recording electrodes so that the propagation time from the stimulus site to the recording electrodes exceeds 2 ms.
  • Because of the unique anatomy and tighter coupling in the cochlea, cochlear implants use small stimulation currents relative to the tens of mA sometimes required for SCS, and thus measured signals in cochlear systems present a relatively lower artefact. To characterize the responses from the dorsal columns, high stimulation currents and close proximity between electrodes are required. Moreover, when using closely spaced electrodes both for stimulus and for measurement the measurement process must overcome artefact directly, in contrast to existing “surgical monitoring” techniques involving measurement electrode(s) which are relatively distant from the stimulus electrode(s).
  • Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.
  • Throughout this specification the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
  • In this specification, a statement that an element may be “at least one of” a list of options is to be understood that the element may be any one of the listed options, or may be any combination of two or more of the listed options.
  • SUMMARY OF THE INVENTION
  • According to a first aspect the present invention provides a method for controlling electrical conditions of tissue, the method comprising:
      • providing a plurality of electrodes including at least one nominal feedback sense electrode and at least one nominal compensation electrode, the electrodes being positioned proximal to the tissue and being in electrical contact with the tissue;
      • connecting a feedback signal from the feedback sense electrode to an input of a feedback amplifier, and referencing the amplifier to a desired electrical value; and
      • connecting an output of the feedback amplifier to the compensation electrode such that the feedback amplifier drives the tissue via the compensation electrode in a feedback arrangement which seeks to drive the feedback signal to the desired electrical value.
  • According to a second aspect the present invention provides a method for measuring a neural response to a stimulus, the method comprising:
      • providing a plurality of electrodes including at least one nominal stimulus electrode, at least one nominal measurement electrode, at least one nominal feedback sense electrode and at least one nominal compensation electrode, the electrodes being positioned proximal to neural tissue and being in electrical contact with the tissue;
      • applying an electrical stimulus to the neural tissue from the stimulus electrode;
      • connecting a feedback signal from the feedback sense electrode to an input of a feedback amplifier, and referencing the amplifier to a desired electrical value;
      • connecting an output of the feedback amplifier to the compensation electrode such that the feedback amplifier drives the neural tissue via the compensation electrode in a feedback arrangement which seeks to drive the neural tissue to the desired electrical value; and
      • obtaining a measurement of a neural response from the measurement electrode.
  • According to a third aspect the present invention provides an implantable device for controlling electrical conditions of tissue, the device comprising:
      • a plurality of electrodes including at least one nominal feedback sense electrode and at least one nominal compensation electrode, the electrodes being configured to be positioned proximal to the tissue to make electrical contact with the tissue;
      • a feedback amplifier configured to be referenced to a desired electrical value and to take as an input a feedback signal from the feedback sense electrode, an output of the feedback amplifier being connected to the compensation electrode such that the feedback amplifier is configured to drive the neural tissue via the compensation electrode in a feedback arrangement which seeks to drive the feedback signal to the desired electrical value.
  • In some embodiments the device of the third aspect may be further configured for measuring a neural response to a stimulus, and may further comprise: one or more nominal stimulus electrodes; one or more nominal sense electrodes; a stimulus source for providing a stimulus to be delivered from the one or more stimulus electrodes to neural tissue; measurement circuitry for amplifying a neural signal sensed at the one or more sense electrodes; and a control unit configured to apply an electrical stimulus to the neural tissue from the stimulus electrode and obtain a measurement of a neural response from the measurement electrode.
  • In some embodiments of the second and third aspects of the invention the feedback amplifier may be disconnected during application of a neural stimulus by disconnecting the feedback sense electrode from the feedback amplifier and/or by disconnecting an output of the feedback amplifier from the compensation electrode. Alternatively, during application of the neural stimulus, for example during the entire period of stimulation, the feedback amplifier may operate and be in connection with the feedback sense electrode and compensation electrode.
  • In preferred embodiments, the feedback sense electrode and the measurement electrode are located outside the dipole formed by the stimulus electrode and the compensating electrode. In such embodiments the operation of the feedback amplifier acts to spatially shield the measurement electrode from the stimulus field, noting that the voltage at points between the poles of a dipole is comparable to the voltage on the electrodes, whereas outside the dipole the voltage drops with the square of distance.
  • Preferred embodiments of the invention may thus reduce artefact by reducing interaction between the stimulus and the measurement recording via a measurement amplifier input capacitance.
  • Some embodiments of the invention may utilise a blanking circuit for blanking the measurement amplifier during and/or close in time to the application of a stimulus. However, alternative embodiments may utilise an unblanked measurement amplifier, which connects a measurement electrode to an analog-to-digital circuit, significantly reducing complexity in the measurement signal chain.
  • The desired electrical value may be zero voltage, i.e. electrical ground. The electrical ground may be referenced to a patient ground electrode distal from the array such as a device body electrode, or to a device ground. Driving the feedback signal to ground will thus act to counteract any non-zero stimulus artefact produced by application of the stimulus.
  • In alternative embodiments a non-zero voltage may in some circumstances be desired in the tissue and the feedback amplifier may thus be referenced to a non-zero electrical value in such embodiments.
  • The electrodes are preferably part of a single electrode array, and are physically substantially identical whereby any electrode of the array may serve as any one of the nominal electrodes at a given time. Alternatively the electrodes may be separately formed, and not in a single array, while being individually positioned proximal to the tissue of interest.
  • In preferred embodiments of the invention, the feedback sense electrode, compensation electrode, stimulus electrode and sense electrode are selected from an implanted electrode array. The electrode array may for example comprise a linear array of electrodes arranged in a single column along the array. Alternatively the electrode array may comprise a two dimensional array having two or more columns of electrodes arranged along the array. Preferably, each electrode of the electrode array is provided with an associated measurement amplifier, to avoid the need to switch the sense electrode(s) to a shared measurement amplifier, as such switching can add to measurement artefact. Providing a dedicated measurement amplifier for each sense electrode is further advantageous in permitting recordings to be obtained from multiple sense electrodes simultaneously.
  • In the first through third aspects of the invention, the measurement may be a single-ended measurement obtained by passing a signal from a single sense electrode to a single-ended amplifier. Alternatively, the measurement may be a differential measurement obtained by passing signals from two measurement electrodes to a differential amplifier. A single stimulus electrode may apply monopolar stimulus referenced to a distal reference point such as an implant case body, alternatively two stimulus electrodes may be used to apply bipolar stimuli, or three stimulus electrodes may be used to apply a tripolar stimulus for example using on stimulus electrode as a cathode and two stimulus electrodes as anodes, and vice versa. The stimulus may be monophasic, biphasic, or otherwise.
  • Embodiments of the invention may prove beneficial in obtaining a CAP measurement which has lower dynamic range and simpler morphology as compared to systems more susceptible to artefact. Such embodiments of the present invention may thus reduce the dynamic range requirements of implanted amplifiers, and may avoid or reduce the complexity of signal processing systems for feature extraction, simplifying and miniaturizing an implanted integrated circuit. Such embodiments may thus be particularly applicable for an automated implanted evoked response feedback system for stimulus control.
  • According to another aspect the present invention provides a computer program product comprising computer program code means to make an implanted processor execute a procedure for controlling electrical conditions of neural tissue, the computer program product comprising computer program code means for carrying out the method of the first or second aspect.
  • According to a further aspect the present invention provides a computer readable storage medium, excluding signals, loaded with computer program code means to make an implanted processor execute a procedure for controlling electrical conditions of neural tissue, the computer readable storage medium loaded with computer program code means for carrying out the method of the first or second aspect.
  • The present invention recognises that when considering spinal cord stimulation, obtaining information about the activity within the spinal segment where stimulation is occurring is highly desirable. Observing the activity and extent of propagation both above (rostrally of) and below (caudally of) the level of stimulation is also highly desirable. The present invention recognises that in order to record the evoked activity within the same spinal segment as the stimulus requires an evoked potential recording system which is capable of recording an SCP within approximately 3 cm of its source, i.e. within approximately 0.3 ms of the stimulus, and further recognises that in order to record the evoked activity using the same electrode array as applied the stimulus requires an evoked potential recording system which is capable of recording an SCP within approximately 7 cm of its source, i.e. within approximately 0.7 ms of the stimulus.
  • In some embodiments the method of the present invention may be applied to measurement of other bioelectrical signals, such as muscle potentials. The method of the present invention may be applicable to any measurement of any voltage within tissue during or after stimulation, and where the stimulation may obscure the voltage being measured. Such situations include the measurement of evoked spinal cord potentials, potentials evoked local to an electrode during deep brain stimulation (DBS), the measurement of EEGs during deep brain stimulation (where the source of the potential is distant from the stimulating electrodes), the measurement of signals in the heart (ECGs) by a pacemaker, the measurement of voltages in stimulated muscles (EMGs), and the measurement of EMGs triggered by the stimulation of distant and controlling nervous tissue.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • An example of the invention will now be described with reference to the accompanying drawings, in which:
  • FIG. 1 illustrates an implantable device suitable for implementing the present invention;
  • FIG. 2 illustrates currents and voltages which can contribute to SCP measurements;
  • FIG. 3 illustrates the equivalent circuit of a typical system for applying a neural stimulus and attempting to measure a neural response;
  • FIG. 4 is an equivalent circuit modelling the tissue/electrode interface and electrode loading;
  • FIG. 5a illustrates a virtual ground system configuration, with double-ended measurement, in accordance with one embodiment of the invention, and FIG. 5b illustrates a virtual ground system configuration, with single-ended measurement, in accordance with another embodiment of the invention; FIG. 5c is a model of the embodiment of FIG. 5b ; FIG. 5d is an equivalent circuit of the model of FIG. 5 c;
  • FIG. 6 is a system schematic illustrating multiplexing of virtual ground functionalities across multiple electrodes;
  • FIG. 7a illustrates an equivalent circuit of the virtual GND embodiment of FIG. 6;
  • FIG. 7b illustrates an active ground “bridge” driver in accordance with an embodiment of the invention;
  • FIG. 8a illustrates the operation of the embodiment of FIG. 6 when the virtual ground function is disabled;
  • FIGS. 8b and 8c show the operation of the circuit of FIG. 6 when the virtual ground function is activated, when experimentally demonstrated on a bench using a saline bath;
  • FIG. 9a illustrates the operation of the embodiment of FIG. 6 when the virtual ground function is disabled, with amplifier blanking; FIG. 9b illustrates the step response of the embodiment of FIG. 6 when the virtual ground function is enabled, with amplifier blanking;
  • FIG. 10a illustrates the performance of the embodiment of FIG. 6 when the virtual ground function is disabled, with amplifier blanking and sinusoid injection; FIG. 10b illustrates the step response of the embodiment of FIG. 6 when the virtual ground function is enabled, with amplifier blanking and sinusoid injection;
  • FIG. 11a plots the measurements from an electrode array in response to a stimulus delivered by the array to a sheep dorsal column, while FIG. 11b is a superimposed plot of similar data, demonstrating timing of respective signal features;
  • FIG. 12 illustrates an alternative embodiment intended for ASIC implementation;
  • FIG. 13 illustrates another embodiment intended for ASIC implementation; and
  • FIG. 14 illustrates yet another embodiment intended for ASIC implementation.
  • DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • FIG. 1 illustrates an implantable device 100 suitable for implementing the present invention. Device 100 comprises an implanted control unit 110, which controls application of a sequence of neural stimuli. In this embodiment the unit 110 is also configured to control a measurement process for obtaining a measurement of a neural response evoked by a single stimulus delivered by one or more of the electrodes 122. Device 100 further comprises an electrode array 120 consisting of a three by eight array of electrodes 122, each of which may be selectively used as the stimulus electrode, sense electrode, compensation electrode or sense electrode.
  • FIG. 2 shows the currents and voltages that contribute to spinal cord potential (SCP) measurements in a typical system of the type shown in FIG. 3. These signals include the stimulus current 202 applied by two stimulus electrodes, which is a charge-balanced biphasic pulse to avoid net charge transfer to or from the tissue and to provide low artefact. Alternative embodiments may instead use three electrodes to apply a tripolar charge balanced stimulus for example where a central electrode. In the case of spinal cord stimulation, the stimulus currents 202 used to provide paraesthesia and pain relief typically consist of pulses in the range of 3-30 mA amplitude, with pulse width typically in the range of 100-400 μs, or alternatively may be paraesthesia-free such as neuro or escalator style stimuli. The stimuli can comprise monophasic or biphasic pulses.
  • The stimulus 202 induces a voltage on adjacent electrodes, referred to as stimulus crosstalk 204. Where the stimuli 202 are SCP stimuli they typically induce a voltage 204 in the range of about 1-5 V on a SCP sense electrode.
  • The stimulus 202 also induces electrode artefact. The mechanism of artefact production can be considered as follows. The stimulus crosstalk can be modelled as a voltage, with an equivalent output impedance. In a human spinal cord, this impedance is typically around 500 ohms per electrode, but will be larger or smaller in different applications. This resistance has little effect in the circuit, but is included for completeness. The stimulus crosstalk drives the measurement amplifiers through the electrode/tissue interface. This interface is shown in FIG. 4 as a set of series capacitance/resistance pairs, modelling a component referred to in the literature as a “Warburg element”. The RC pairs model the complex diffusion behaviour at the electrode surface, and have time constants from micro-seconds to seconds. The cables from the electrode to the amplifier add capacitance which loads the electrode, along with the resistive input impedance of the amplifier itself. Typical loading would be 200 pF of capacitance and 1 megohms of resistance. Following this is an ideal amplifier in this equivalent circuit of FIG. 4.
  • The electrode artefact is the response of the electrode/tissue interface, when driven by the stimulus crosstalk and loaded by the capacitance and resistance at the amplifier input. It can be observed, either with a circuit simulator or in a laboratory. It can also be observed that the sign of the artefact is opposite for capacitive and resistive loading. Electrical artefact usually also arises from the behaviour of the amplifier circuitry in response to these particular circumstances.
  • It is possible to reduce artefact by reducing the loading on the electrode, however in practical situations there are limits to how low this capacitance can be made. Increasing the electrode surface area also decreases artefact but again in practical situations there will be limits to the electrode size. Artefact can also be reduced by adding resistance or capacitance to the amplifier input relying on the opposite sign of the artefact produced by these terms. However, this only works to a limited extent, and changing the size of the electrode changes the size of the required compensation components which makes it difficult to make a general purpose amplifier that can be connected to a range of electrodes. One can also reduce artefact by reducing the size of the stimulus crosstalk, and this is the aim of the virtual ground circuit embodiment of this invention shown in FIG. 5, which relates to evoking and measuring a neural response.
  • Referring again to FIGS. 2 and 3, an appropriate electrical stimulus 202 will induce nerves to fire, and thereby produces an evoked neural response 206. In the spinal cord, the neural response 206 can have two major components: a fast response lasting ˜2 ms and a slow response lasting ˜15 ms. The slow response only appears at stimulation amplitudes which are larger than the minimum stimulus required to elicit a fast response. Many therapeutic stimuli paradigms seek to evoke fast responses only, and to avoid evoking any slow response. Thus, the neural response of interest for neural response measurements concludes within about 2 ms. The amplitude of the evoked response seen by epidural electrodes is typically no more than hundreds of microvolts, but in some clinical situations can be only tens of microvolts.
  • In practical implementation a measurement amplifier used to measure the evoked response does not have infinite bandwidth, and will normally have infinite impulse response filter poles, and so the stimulus crosstalk 204 will produce an output 208 during the evoked response 206, this output being referred to as electrical artefact.
  • Electrical artefact can be in the hundreds of millivolts as compared to a SCP of interest in the tens of microvolts. Electrical artefact can however be somewhat reduced by suitable choice of a high-pass filter pole frequency.
  • The measurement amplifier output 210 will therefore contain the sum of these various contributions 202-208. Separating the evoked response of interest (206) from the artefacts 204 and 208 is a significant technical challenge. For example, to resolve a 10 μV SCP with 1 μV resolution, and have at the input a 5V stimulus, requires an amplifier with a dynamic range of 134 dB. As the response can overlap the stimulus this represents a difficult challenge of amplifier design.
  • FIG. 5a illustrates a neural stimulus and response system providing differential neural measurements and using a shared electrode for measurement and for feedback sense. Alternative embodiments could use two separate electrodes for measurements and feedback sense, respectively.
  • FIG. 5b illustrates a configuration of device 100 for controlling electrical conditions of neural tissue in accordance with another embodiment of the present invention, providing single ended neural measurements. In the configuration of FIG. 5b the device has a current source 502 which drives current into tissue via stimulus electrode 504 in order to stimulate the neural tissue and evoke a neural response. A feedback sense electrode 506, compensation electrode 508 and measurement electrode 510 are also provided. The electrodes 504-510 are positioned proximal to neural tissue to make electrical contact with the tissue. A feedback amplifier 512 is referenced to ground 514 and takes as an input a feedback signal from the feedback sense electrode 506. An output of the feedback amplifier 512 is connected to the compensation electrode 508 such that the feedback amplifier 512 is configured to drive the tissue via the compensation electrode 508 in a feedback arrangement which seeks to drive the feedback signal to ground. This mechanism will thus operate to quash stimulus artefact at the tissue electrode interface, improving measurement conditions for neural response measurement circuitry 516.
  • As shown in FIG. 5c , the adjacent stimulus, compensation, feedback sense and measurement electrodes in contact with resistive tissue can be modelled as respective contacts each connected to a tissue rail by a respective resistance R1, R2, R3 and R4.
  • An equivalent circuit of FIG. 5c is shown in FIG. 5d . Stimulus and stimulus artefact occurring upon the stimulus electrode creates a current I through R1. Feedback amplifier 512 operates to maintain zero current at each amplifier input, and also operates to maintain the voltage at each input to be identical. Therefore in the configuration of FIGS. 5a-d , the voltage at each amplifier input is zero, because the positive input is referenced to ground. Moreover, current through R3 is forced to zero, being the same as the input current to the amplifier 312. This ensures that there is no voltage differential across R3, and that the tissue node must therefore be forced to ground, in this model. This effect is referred to herein as providing a virtual ground.
  • The voltage caused by the current stimulus travels at the speed of light in the tissue medium, whereas an evoked action potential in the neural tissue travels at around 60 m/s. When the feedback sense electrode is subject to (or senses) the evoked response it will cancel the stimulus crosstalk in the tissue, but due to the larger propagation delay, the voltages produced by the evoked response at different electrodes (such as the measurement electrodes) will differ, and can be recorded. It will simply be the voltage that would otherwise by recorded as the difference between the measurement electrode and the feedback sense electrode. Alternatively, the sense electrode can be placed elsewhere in the tissue further from the stimulus electrode(s), and substantially no cancellation of the evoked response will then occur, although the electrode will be subject to other electrical signals in the body from muscles, and other nerve bundles. This might be the situation when the sense electrode is on the body of an implant, with the stimulating electrodes on a lead.
  • FIG. 6 is a system schematic illustrating multiplexing of virtual ground functionalities across multiple electrodes, applicable to the embodiment of FIG. 5a or FIG. 5b . This shows the buffer at the output of the reference MUX. A set of electrodes is connected to a current source and a set of amplifiers. The “current source MUX” allows the stimulus current to be directed to any electrode. The “Ground MUX” allows any electrode to be chosen as the second of the pair of stimulating electrodes. Switches “Std” and “VG” allow the circuit to selectively provide conventional stimulation, or stimulation according to this invention. A third multiplexor selects the electrode to be used as the reference point (feedback sense electrode). Once the electrode configuration has been chosen, the circuit operates according to FIGS. 5a-d . Each of the N electrodes of the array of FIG. 6 may thus, at any given time, nominally serve as any one of the stimulus, sense or measurement electrode.
  • The circuit of FIG. 6 may alternatively be modified such that the reference voltage passed to the virtual ground feedback amplifier is a combination of the voltages on the measurement electrodes, e.g. the average of two or more electrode voltages.
  • In principle, the virtual ground circuit of the embodiment of FIG. 5b provides for the stimulus electrode 504 to be driven by a current source. An op-amp circuit 512 and compensating electrode 508 provides a feedback loop holding the tissue voltage, as measured at a sense electrode 510, to 0 V. In an ideal situation, the voltage on the compensating electrode 508 is identical in amplitude but of opposite polarity to the voltage on the stimulating electrode 504. This ideally leaves the potential on a measurement electrode 510 unchanged by the stimulation and thus significantly improves conditions for measurement of an evoked response with reduced artefact.
  • Referring to FIG. 6, it is noted that the components making up the virtual ground circuit are spread throughout the device 100, having components in the reference multiplexer (Ref. MUX). As shown in FIG. 6, an electrode is wired to the inverting input multiplexer. This includes a buffer to drive the capacitance on the inputs of the array of amplifiers, and the virtual ground amplifier. These components, their parasitics, and the capacitance of the wiring on the circuit boards from which the system is made must be considered in order to design a stable circuit.
  • FIG. 7a illustrates the actual circuit used for the amplifier in the reference multiplexer (“Ref. MUX”) of FIG. 6, in the preferred embodiment of the virtual ground circuit. The reference signal selected by the MUX is buffered before it is passed to the amplifier negative inputs, and the virtual ground circuit. The buffer uses a current feedback amplifier, because this amplifier is inside the virtual ground feedback loop and this amplifier introduces less phase shift than a voltage feedback device. This has been used both for experimental verification in a saline bath (from which the attached figures were obtained) and in a human subject.
  • As shown in FIG. 7b , the virtual ground circuit of this embodiment includes an inverting amplifier and a high-speed buffer. The op-amp alone does not have the current sourcing capability to drive the current available from the current sources, which can deliver up to 50 mA. The 470 p capacitor provides dominant pole compensation to the loop. The switches are paralleled to provide low impedance paths, and match the switch configuration of FIG. 6.
  • The FETs Q902 and Q903 in FIG. 7b , from the input to the supplies, provide electrostatic discharge (ESD) protection. The capacitor C900 and pulldown resistor R901 set the DC bias point for the loop.
  • FIG. 8a illustrates the problem of stimulus crosstalk when the virtual ground function is disabled. Trace 801 is from Electrode 1 (stimulus electrode), trace 804 is from Electrode 2 (ground electrode), trace 802 is from Electrode 4 (first measurement electrode), and trace 803 is from Electrode 5 (second measurement electrode).
  • FIGS. 8b and 8c show the behaviour of the circuit of FIG. 6 when the virtual ground function is activated, when experimentally implemented on a bench using an actual saline bath. FIGS. 8b and 8c show the response to a 10 mA biphasic pulse stimulus in 1/10 PBS (phosphate buffered saline). As can be seen, now the stimulus and feedback electrodes (811 and 814) swing in opposite directions, while the measurement electrodes (812 and 813) mostly stay at ground. The ringing at the measurement electrodes is the response of the feedback loop to the very high slew-rate current source edges, but represents significantly reduced artefact as compared to FIG. 8 a.
  • FIG. 9a shows artefact with virtual ground disabled, and in particular shows the behaviour of the circuit of FIG. 6 when the virtual ground function is deactivated, when experimentally implemented on a bench using an actual saline bath. In FIG. 9a , the stimulus occurred and concluded at some time prior to t=0.6 ms, at which time the amplifiers were blanked. The amplifiers were then unblanked at t=0.6 ms. FIG. 9 shows the measured voltages on two measurement electrodes, with a peak artefact of around 400 uV.
  • FIG. 9b shows the amplifier outputs with virtual ground enabled, but otherwise identical stimulation as produced FIG. 9a . As can be seen, when using virtual ground in the circuit of FIG. 6, artefact is about 100 uV, or smaller by about 75%.
  • FIG. 10a shows the amplifier output for the same experiment as FIG. 9a , but with a 50 uV pp sinusoidal signal injected in series with electrode 4, to give an idea of how an evoked response would superimpose upon the artefact. The sinusoidal signal cannot be easily seen before about 1.5 ms, i.e. the first 1 ms of measurement time is obscured by the artefact.
  • FIG. 10b is for the same experiment as FIG. 10a but with virtual ground enabled. Here, the sinusoidal signal can be seen distinct from the artefact from around 0.75 ms, or about 750 us (80%) earlier than for FIG. 10a relative to the unblanking time.
  • FIG. 11a shows the evoked response in a sheep dorsal column. In particular, FIG. 11a plots the measurements obtained simultaneously from 22 electrodes of a 24 electrode array in response to a stimulus delivered by two adjacent electrodes positioned centrally in the array. As can be seen, evoked responses propagate simultaneously both caudally and rostrally from the central stimulus site. The current required to evoke such a response in a sheep is much lower than in humans, and the evoked response signals are higher, so artefact is less of a problem. In other regards the sheep signals are similar to the human case. In FIG. 11a the amplifiers are unblanked at approximately 0.75 msec and the response finishes within another 0.75 ms. FIG. 11b is a superimposed plot of similar data, demonstrating timing of respective signal features when measuring on multiple electrodes at increasing distance from the stimulus site. FIGS. 11a and 11b illustrate the importance of reducing artefact during the period immediately after stimulation.
  • In a first mode of operation in accordance with some embodiments of the invention, at the end of stimulation the stimulation electrodes are both disconnected. The bath (or subject) is floating at this point, as there is no connection between the bath and the circuit ground. Since the amplifiers are all differential, taking the difference between the reference electrode and the other epidural electrodes will compensate for any change in voltage. This mode of operation reflects the logic that other choices of which electrode to ground seem likely to worsen artefact: connecting a stimulation electrode will cause the bath potential to change as the electrode voltage settles; connecting an epidural electrode to GND might put a transient on it which would be seen on all the channels.
  • In a second mode of operation of other embodiments of the invention, the VG circuit remains active after the stimulation, which makes the bioelectrical situation quite different. The voltage on the compensation electrode will change as the electrode potentials settle, but the VG loop will compensate for this so it will not affect the bath potential. At the same time, the VG circuit can hold the bath at a fixed voltage—GND. The VG circuit will attempt to keep the epidural space at a static voltage, namely GND.
  • In another embodiment, the present invention is implemented in an application-specific integrated circuit (ASIC). The primary difference that is encountered in an ASIC implementation is that whereas most PCB amplifiers and components are intended for split supply operation, most ASIC designs, especially one intended for implantable operation, will operate from a single supply. Also, in an ASIC, the desire to produce a low-cost design is increased, as an ASIC implementation would be preferable for commercial exploitation.
  • FIG. 12 shows a design intended for ASIC operation. The design uses separate current sources to provide anodic and cathodic current. These are connected to an electrode array. They also electrodes to be arbitrarily connected to the output and input of the virtual ground amplifier. The point “Vgref” provides the bias point for the amplifier; this would typically be half the power supply. In this case the power supply is called “VDDH”, indicating it is a high-voltage supply suitable for tissue stimulation.
  • The switched connections directly to VDDH and GND allow stimulation modes that do not use the virtual ground amplifier. In the design of FIG. 5a , the virtual ground amplifier provides the entire current for the second of the two stimulating electrodes. To create the ASIC implementation some changes were required. In the PCB design of FIG. 5a , the amplifier output provides the entire opposite current to that of the output of the current driver. This requires an amplifier with a considerable output drive, for example if the current source can drive 50 mA, so must the amplifier. An amplifier with this current drive, stable in a feedback loop, and with the required bandwidth can be difficult to obtain, although they are available.
  • Thus a problem in an ASIC implementation is to provide the virtual ground amplifier with sufficient current capability to balance the current source; this takes considerable silicon area which incurs cost. Noting that both positive and negative current sources are available in the ASIC, the present embodiment thus uses the circuit of FIG. 13, suitable for integrated circuit implementation. This implementation requires the use of matched positive and negative current drivers. It also operates from a single supply, simplifying the system implementation. The feedback loop holds the tissue voltage at a stable voltage—the midpoint of the two supplies. The amplifier only has to source or sink a current equal to the mismatch between the two amplifiers, denoted dl in FIG. 13. Since the current source has a high output impedance, the load seen by the amplifier is unchanged as compared to the case of FIG. 5a where the amplifier provides all the drive, however the amplifier no longer has to provide high current. In a case where the current sources match to 10%, a 0.1 reduction in capability is achieved.
  • FIG. 14 illustrates yet another embodiment, in which the amplifier is connected as a unity gain buffer. It is noted that this proposal may be integrated into the design of Australian Provisional Patent Application No. 2012904838.
  • It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. For example while application of the method to neural stimulation is described, it is to be appreciated that the techniques described in this patent apply in other situations involving measurement of a voltage within tissue during or after stimulation.
  • The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

Claims (11)

1. A method for measuring a neural response to a stimulus, the method comprising:
providing a plurality of implantable electrodes including at least one nominal stimulus electrode, at least one nominal measurement electrode, at least one nominal feedback sense electrode and at least one nominal compensation electrode, the electrodes being implanted proximal to a neural tissue and being in electrical contact with the neural tissue;
applying an electrical stimulus to the neural tissue from the at least one stimulus electrode;
connecting a feedback signal from the at least one feedback sense electrode to an input of a feedback amplifier, and referencing the feedback amplifier to a desired electrical value;
connecting an output of the feedback amplifier to the at least one compensation electrode such that the feedback amplifier drives the neural tissue via the at least one compensation electrode in a feedback arrangement which seeks to drive the neural tissue to the desired electrical value; and
obtaining a measurement of a neural response from the at least one measurement electrode.
2. The method of claim 1 wherein the desired electrical value is electrical ground referenced to a patient ground electrode distal from the at least one feedback sense electrode.
3. The method of claim 1 further comprising disconnecting the feedback amplifier during application of the electrical stimulus.
4. The method of claim 3 wherein the feedback amplifier is disconnected by disconnecting the at least one feedback sense electrode from the feedback amplifier.
5. The method of claim 3 wherein the feedback amplifier is disconnected by disconnecting an output of the feedback amplifier from the at least one compensation electrode.
6. The method of claim 1 wherein, during the entire period of stimulation, the feedback amplifier operates and is in connection with the at least one feedback sense electrode and at least one compensation electrode.
7. The method of claim 1 wherein the at least one feedback sense electrode and the at least one measurement electrode are located outside a dipole formed by the at least one stimulus electrode and the at least one compensating electrode.
8. An implantable device for controlling electrical conditions of tissue, the device comprising:
a plurality of implantable electrodes including at least one nominal feedback sense electrode, at least one nominal compensation electrode, at least one nominal stimulus electrode, and at least one nominal sense electrode; the electrodes being configured to be implanted proximal to the tissue to make electrical contact with the tissue;
a stimulus source for providing an electrical stimulus to be delivered from the at least one stimulus electrode to neural tissue;
measurement circuitry for amplifying a neural signal sensed at the at least one sense electrode; and
a feedback amplifier configured to be referenced to a desired electrical value and to take as an input a feedback signal from the feedback sense electrode, an output of the feedback amplifier being connected to the compensation electrode such that the feedback amplifier is configured to drive the neural tissue via the compensation electrode in a feedback arrangement which seeks to drive the feedback signal to the desired electrical value.
9. The device of claim 8 wherein the feedback amplifier is configured to operate in connection with the feedback sense electrode and compensation electrode during an entire period of the electrical stimulus.
10. The device of claim 8 wherein the desired electrical value is electrical ground referenced to a patient ground electrode distal from the feedback sense electrode.
11. The device of claim 8 wherein the feedback sense electrode and the measurement electrode are located outside a dipole formed by the stimulus electrode and the compensating electrode.
US16/224,641 2012-11-06 2018-12-18 Method and system for controlling electrical conditions of tissue Active 2035-02-17 US11389098B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/224,641 US11389098B2 (en) 2012-11-06 2018-12-18 Method and system for controlling electrical conditions of tissue
US17/664,568 US11944439B2 (en) 2012-11-06 2022-05-23 Method and system for controlling electrical conditions of tissue

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2012904836 2012-11-06
AU2012904838A AU2012904838A0 (en) 2012-11-06 Method and System for Controlling Electrical Conditions of Tissue II
AU2012904836A AU2012904836A0 (en) 2012-11-06 Method and System for Controlling Electrical Conditions of Tissue
AU2012904838 2012-11-06
PCT/AU2013/001279 WO2014071445A1 (en) 2012-11-06 2013-11-06 Method and system for controlling electrical conditions of tissue
US201514440873A 2015-05-05 2015-05-05
US16/224,641 US11389098B2 (en) 2012-11-06 2018-12-18 Method and system for controlling electrical conditions of tissue

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/AU2013/001279 Continuation WO2014071445A1 (en) 2012-11-06 2013-11-06 Method and system for controlling electrical conditions of tissue
US14/440,873 Continuation US10206596B2 (en) 2012-11-06 2013-11-06 Method and system for controlling electrical conditions of tissue

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/664,568 Continuation US11944439B2 (en) 2012-11-06 2022-05-23 Method and system for controlling electrical conditions of tissue

Publications (2)

Publication Number Publication Date
US20190216343A1 true US20190216343A1 (en) 2019-07-18
US11389098B2 US11389098B2 (en) 2022-07-19

Family

ID=50683822

Family Applications (3)

Application Number Title Priority Date Filing Date
US14/440,873 Active 2034-08-02 US10206596B2 (en) 2012-11-06 2013-11-06 Method and system for controlling electrical conditions of tissue
US16/224,641 Active 2035-02-17 US11389098B2 (en) 2012-11-06 2018-12-18 Method and system for controlling electrical conditions of tissue
US17/664,568 Active 2033-11-18 US11944439B2 (en) 2012-11-06 2022-05-23 Method and system for controlling electrical conditions of tissue

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14/440,873 Active 2034-08-02 US10206596B2 (en) 2012-11-06 2013-11-06 Method and system for controlling electrical conditions of tissue

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/664,568 Active 2033-11-18 US11944439B2 (en) 2012-11-06 2022-05-23 Method and system for controlling electrical conditions of tissue

Country Status (6)

Country Link
US (3) US10206596B2 (en)
EP (1) EP2908904B1 (en)
AU (1) AU2013344311B2 (en)
DK (1) DK2908904T3 (en)
ES (1) ES2834958T3 (en)
WO (1) WO2014071445A1 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10568559B2 (en) 2011-05-13 2020-02-25 Saluda Medical Pty Ltd Method and apparatus for measurement of neural response
US10588524B2 (en) 2011-05-13 2020-03-17 Saluda Medical Pty Ltd Method and apparatus for measurement of neural response
US10588698B2 (en) 2014-12-11 2020-03-17 Saluda Medical Pty Ltd Implantable electrode positioning
US10632307B2 (en) 2014-07-25 2020-04-28 Saluda Medical Pty Ltd Neural stimulation dosing
US10849525B2 (en) 2015-05-31 2020-12-01 Saluda Medical Pty Ltd Monitoring brain neural activity
US10894158B2 (en) 2015-04-09 2021-01-19 Saluda Medical Pty Ltd Electrode to nerve distance estimation
US11006857B2 (en) 2015-06-01 2021-05-18 Closed Loop Medical Pty Ltd Motor fibre neuromodulation
US11006846B2 (en) 2014-11-17 2021-05-18 Saluda Medical Pty Ltd Method and device for detecting a neural response in neural measurements
US11045129B2 (en) 2011-05-13 2021-06-29 Saluda Medical Pty Ltd. Method and apparatus for estimating neural recruitment
US11110270B2 (en) 2015-05-31 2021-09-07 Closed Loop Medical Pty Ltd Brain neurostimulator electrode fitting
US11172864B2 (en) 2013-11-15 2021-11-16 Closed Loop Medical Pty Ltd Monitoring brain neural potentials
US11179091B2 (en) 2016-06-24 2021-11-23 Saluda Medical Pty Ltd Neural stimulation for reduced artefact
US11191966B2 (en) 2016-04-05 2021-12-07 Saluda Medical Pty Ltd Feedback control of neuromodulation
US11219766B2 (en) 2014-12-11 2022-01-11 Saluda Medical Pty Ltd Method and device for feedback control of neural stimulation
US11324427B2 (en) 2011-05-13 2022-05-10 Saluda Medical Pty Ltd Method and apparatus for measurement of neural response
US11337658B2 (en) 2013-11-22 2022-05-24 Saluda Medical Pty Ltd Method and device for detecting a neural response in a neural measurement
US11413460B2 (en) 2011-05-13 2022-08-16 Saluda Medical Pty Ltd Method and apparatus for application of a neural stimulus
US11457849B2 (en) 2014-05-05 2022-10-04 Saluda Medical Pty Ltd Neural measurement
US11944439B2 (en) 2012-11-06 2024-04-02 Saluda Medical Pty Ltd Method and system for controlling electrical conditions of tissue
US11944820B2 (en) 2018-04-27 2024-04-02 Saluda Medical Pty Ltd Neurostimulation of mixed nerves

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8972022B2 (en) 2010-06-18 2015-03-03 Cardiac Pacemakers, Inc. Methods and apparatus for controlling neurostimulation using evoked responses
US10918872B2 (en) 2015-01-19 2021-02-16 Saluda Medical Pty Ltd Method and device for neural implant communication
US10406368B2 (en) 2016-04-19 2019-09-10 Boston Scientific Neuromodulation Corporation Pulse generator system for promoting desynchronized firing of recruited neural populations
US11612751B2 (en) 2017-08-11 2023-03-28 Boston Scientific Neuromodulation Corporation Stimulation configuration variation to control evoked temporal patterns
US11129987B2 (en) 2017-10-04 2021-09-28 Boston Scientific Neuromodulation Corporation Adjustment of stimulation in a stimulator using detected evoked compound action potentials
WO2019136072A1 (en) 2018-01-08 2019-07-11 Boston Scientific Neuromodulation Corporation Automatic adjustment of sub-perception therapy in an implantable stimulator using detected compound action potentials
EP3752244A4 (en) 2018-02-15 2022-03-09 Saluda Medical Pty Limited Power efficient stimulators
US20190275331A1 (en) 2018-03-12 2019-09-12 Boston Scientific Neuromodulation Corporation Neural Stimulation with Decomposition of Evoked Compound Action Potentials
US10974042B2 (en) 2018-03-26 2021-04-13 Boston Scientific Neuromodulation Corporation System and methods for heart rate and electrocardiogram extraction from a spinal cord stimulation system
US11040202B2 (en) 2018-03-30 2021-06-22 Boston Scientific Neuromodulation Corporation Circuitry to assist with neural sensing in an implantable stimulator device
WO2019231796A1 (en) * 2018-06-01 2019-12-05 Boston Scientific Neuromodulation Corporation Artifact reduction in a sensed neural response
WO2019246582A1 (en) 2018-06-21 2019-12-26 Medtronic, Inc. Ecap based control of electrical stimulation therapy
EP4085971B1 (en) 2018-06-21 2023-12-13 Medtronic, Inc. Ecap based control of electrical stimulation therapy
CA3104878A1 (en) * 2018-06-27 2020-01-02 Boston Scientific Neuromodulation Corporation Stimulation field modelling in an implantable stimulator device
WO2020082128A1 (en) 2018-10-23 2020-04-30 Saluda Medical Pty Ltd Current source for neurostimulation
AU2020220021B2 (en) * 2019-02-08 2022-08-11 Boston Scientific Neuromodulation Corporation Spinal cord stimulation for dorsal column recruitment or suppression using anodic and cathodic pulses
CN113613709A (en) 2019-03-29 2021-11-05 波士顿科学神经调制公司 Circuit for assisting neural sensing in an implantable stimulator device in the presence of stimulation artifacts
CA3128134A1 (en) 2019-03-29 2020-10-08 Boston Scientific Neuromodulation Corporation Neural sensing in an implantable stimulator device during the provision of active stimulation
US11504526B2 (en) 2019-05-30 2022-11-22 Boston Scientific Neuromodulation Corporation Methods and systems for discrete measurement of electrical characteristics
US11623095B2 (en) 2019-06-20 2023-04-11 Boston Scientific Neuromodulation Corporation Methods and systems for interleaving waveforms for electrical stimulation and measurement
US11547855B2 (en) 2019-10-25 2023-01-10 Medtronic, Inc. ECAP sensing for high frequency neurostimulation
US11931582B2 (en) 2019-10-25 2024-03-19 Medtronic, Inc. Managing transient overstimulation based on ECAPs
EP4153055A1 (en) * 2020-05-18 2023-03-29 Saluda Medical Pty Ltd Neural recording with stimulus crosstalk compensation
US11857793B2 (en) 2020-06-10 2024-01-02 Medtronic, Inc. Managing storage of sensed information
US11707626B2 (en) 2020-09-02 2023-07-25 Medtronic, Inc. Analyzing ECAP signals
US11896828B2 (en) 2020-10-30 2024-02-13 Medtronic, Inc. Implantable lead location using ECAP
CN112316306A (en) * 2021-01-04 2021-02-05 北京品驰医疗设备有限公司 Programme-controlled device for selective setting of directional electrode neuromodulation and related system

Family Cites Families (342)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3724467A (en) 1971-04-23 1973-04-03 Avery Labor Inc Electrode implant for the neuro-stimulation of the spinal cord
US3736434A (en) 1971-06-07 1973-05-29 Westinghouse Air Brake Co Fail-safe electronic comparator circuit
US3817254A (en) 1972-05-08 1974-06-18 Medtronic Inc Transcutaneous stimulator and stimulation method
US3898472A (en) 1973-10-23 1975-08-05 Fairchild Camera Instr Co Occupancy detector apparatus for automotive safety system
US4158196A (en) 1977-04-11 1979-06-12 Crawford George E Jr Man-machine interface system
FR2419720A1 (en) 1978-03-14 1979-10-12 Cardiofrance Co IMPLANTABLE HEART STIMULATOR WITH THERAPEUTIC AND DIAGNOSTIC FUNCTIONS
US4474186A (en) 1979-07-17 1984-10-02 Georgetown University Computerized electro-oculographic (CEOG) system with feedback control of stimuli
US4807643A (en) 1982-08-16 1989-02-28 University Of Iowa Research Foundation Digital electroneurometer
US4628934A (en) 1984-08-07 1986-12-16 Cordis Corporation Method and means of electrode selection for pacemaker with multielectrode leads
CA1279101C (en) 1985-10-10 1991-01-15 Christopher Van Den Honert Multichannel electrical stimulator with improved channel isolation
US4817628A (en) 1985-10-18 1989-04-04 David L. Zealear System and method for evaluating neurological function controlling muscular movements
DE3831809A1 (en) 1988-09-19 1990-03-22 Funke Hermann DEVICE DETERMINED AT LEAST PARTLY IN THE LIVING BODY
US5143081A (en) 1990-07-27 1992-09-01 New York University Randomized double pulse stimulus and paired event analysis
US5172690A (en) 1990-10-26 1992-12-22 Telectronics Pacing Systems, Inc. Automatic stimulus artifact reduction for accurate analysis of the heart's stimulated response
US5156154A (en) 1991-03-08 1992-10-20 Telectronics Pacing Systems, Inc. Monitoring the hemodynamic state of a patient from measurements of myocardial contractility using doppler ultrasound techniques
US5139020A (en) 1991-03-08 1992-08-18 Telectronics Pacing Systems, Inc. Method and apparatus for controlling the hemodynamic state of a patient based on systolic time interval measurements detecting using doppler ultrasound techniques
US5184615A (en) 1991-03-08 1993-02-09 Telectronics Pacing Systems, Inc. Apparatus and method for detecting abnormal cardiac rhythms using evoked potential measurements in an arrhythmia control system
US5188106A (en) 1991-03-08 1993-02-23 Telectronics Pacing Systems, Inc. Method and apparatus for chronically monitoring the hemodynamic state of a patient using doppler ultrasound
US5215100A (en) 1991-04-29 1993-06-01 Occupational Preventive Diagnostic, Inc. Nerve condition monitoring system and electrode supporting structure
DE69119242T3 (en) * 1991-07-15 2000-07-20 Medtronic Inc MEDICAL STIMULATION DEVICE WITH AN OPERATIONAL AMPLIFIER OUTPUT CIRCUIT
US5324311A (en) 1992-09-04 1994-06-28 Siemens Pacesetter, Inc. Coaxial bipolar connector assembly for implantable medical device
US5497781A (en) 1992-10-30 1996-03-12 Chen; Yunquan Recording biological signals using Hilbert transforms
CA2152049C (en) 1992-12-22 2004-03-23 Tony Mikeal Nygard Telemetry system and apparatus
GB9302335D0 (en) 1993-02-05 1993-03-24 Macdonald Alexander J R Electrotherapeutic apparatus
US5417719A (en) 1993-08-25 1995-05-23 Medtronic, Inc. Method of using a spinal cord stimulation lead
US5431693A (en) 1993-12-10 1995-07-11 Intermedics, Inc. Method of verifying capture of the heart by a pacemaker
US5458623A (en) 1994-03-04 1995-10-17 Telectronics Pacing Systems, Inc. Automatic atrial pacing threshold determination utilizing an external programmer and a surface electrogram
US5476486A (en) 1994-03-04 1995-12-19 Telectronics Pacing Systems, Inc. Automatic atrial pacing pulse threshold determination utilizing an external programmer and a V-sense electrode
JP2596372B2 (en) 1994-04-21 1997-04-02 日本電気株式会社 Evoked potential measurement device
AUPM883794A0 (en) 1994-10-17 1994-11-10 University Of Melbourne, The Multiple pulse stimulation
US5785651A (en) 1995-06-07 1998-07-28 Keravision, Inc. Distance measuring confocal microscope
US6066163A (en) 1996-02-02 2000-05-23 John; Michael Sasha Adaptive brain stimulation method and system
US6463328B1 (en) 1996-02-02 2002-10-08 Michael Sasha John Adaptive brain stimulation method and system
US5702429A (en) 1996-04-04 1997-12-30 Medtronic, Inc. Neural stimulation techniques with feedback
FR2796562B1 (en) 1996-04-04 2005-06-24 Medtronic Inc TECHNIQUES FOR STIMULATING LIVING TISSUE AND RECORDING WITH LOCAL CONTROL OF ACTIVE SITES
AU714617B2 (en) 1996-04-04 2000-01-06 Medtronic, Inc. Living tissue stimulation and recording techniques
US6493576B1 (en) 1996-06-17 2002-12-10 Erich Jaeger Gmbh Method and apparatus for measuring stimulus-evoked potentials of the brain
DE69728173T2 (en) 1996-06-20 2005-02-03 Advanced Bionics Corp., Sylmar SELF-ADJUSTING COCHLEAR IMPLANT SYSTEM
US6246912B1 (en) 1996-06-27 2001-06-12 Sherwood Services Ag Modulated high frequency tissue modification
US5792212A (en) 1997-03-07 1998-08-11 Medtronic, Inc. Nerve evoked potential measurement system using chaotic sequences for noise rejection
US5895416A (en) 1997-03-12 1999-04-20 Medtronic, Inc. Method and apparatus for controlling and steering an electric field
US5873898A (en) 1997-04-29 1999-02-23 Medtronic, Inc. Microprocessor capture detection circuit and method
US7628761B2 (en) 1997-07-01 2009-12-08 Neurometrix, Inc. Apparatus and method for performing nerve conduction studies with localization of evoked responses
US5999848A (en) 1997-09-12 1999-12-07 Alfred E. Mann Foundation Daisy chainable sensors and stimulators for implantation in living tissue
US6522932B1 (en) 1998-02-10 2003-02-18 Advanced Bionics Corporation Implantable, expandable, multicontact electrodes and tools for use therewith
CA2223668C (en) 1998-02-23 2000-07-11 James Stanley Podger The strengthened quad antenna structure
US6421566B1 (en) 1998-04-30 2002-07-16 Medtronic, Inc. Selective dorsal column stimulation in SCS, using conditioning pulses
US6027456A (en) 1998-07-10 2000-02-22 Advanced Neuromodulation Systems, Inc. Apparatus and method for positioning spinal cord stimulation leads
US7231254B2 (en) 1998-08-05 2007-06-12 Bioneuronics Corporation Closed-loop feedback-driven neuromodulation
US7277758B2 (en) 1998-08-05 2007-10-02 Neurovista Corporation Methods and systems for predicting future symptomatology in a patient suffering from a neurological or psychiatric disorder
US6212431B1 (en) 1998-09-08 2001-04-03 Advanced Bionics Corporation Power transfer circuit for implanted devices
US20060217782A1 (en) 1998-10-26 2006-09-28 Boveja Birinder R Method and system for cortical stimulation to provide adjunct (ADD-ON) therapy for stroke, tinnitus and other medical disorders using implantable and external components
US6253109B1 (en) 1998-11-05 2001-06-26 Medtronic Inc. System for optimized brain stimulation
US6114164A (en) 1998-12-07 2000-09-05 The Regents Of The University Of Michigan System and method for emulating an in vivo environment of a muscle tissue specimen
US6898582B2 (en) 1998-12-30 2005-05-24 Algodyne, Ltd. Method and apparatus for extracting low SNR transient signals from noise
US6909917B2 (en) 1999-01-07 2005-06-21 Advanced Bionics Corporation Implantable generator having current steering means
US6600955B1 (en) 1999-07-21 2003-07-29 Med-El Elektromedizinishe Geraete Gmbh Multichannel cochlear implant with neural response telemetry
US6516227B1 (en) 1999-07-27 2003-02-04 Advanced Bionics Corporation Rechargeable spinal cord stimulator system
US6381496B1 (en) 1999-10-01 2002-04-30 Advanced Bionics Corporation Parameter context switching for an implanted device
US6587724B2 (en) 1999-12-17 2003-07-01 Advanced Bionics Corporation Magnitude programming for implantable electrical stimulator
US6473649B1 (en) 1999-12-22 2002-10-29 Cardiac Pacemakers, Inc. Rate management during automatic capture verification
US20020055688A1 (en) 2000-05-18 2002-05-09 Jefferson Jacob Katims Nervous tissue stimulation device and method
AU2001268473A1 (en) 2000-06-20 2002-01-02 Advanced Bionics Corporation Apparatus for treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion
US7305268B2 (en) 2000-07-13 2007-12-04 Northstar Neurscience, Inc. Systems and methods for automatically optimizing stimulus parameters and electrode configurations for neuro-stimulators
US7831305B2 (en) 2001-10-15 2010-11-09 Advanced Neuromodulation Systems, Inc. Neural stimulation system and method responsive to collateral neural activity
WO2002038031A2 (en) 2000-10-30 2002-05-16 Neuropace, Inc. System and method for determining stimulation parameters for the treatment of epileptic seizures
US7089059B1 (en) 2000-11-03 2006-08-08 Pless Benjamin D Predicting susceptibility to neurological dysfunction based on measured neural electrophysiology
US7451000B2 (en) 2000-11-29 2008-11-11 Cochlear Limited Pre-curved cochlear implant electrode array
US6594524B2 (en) 2000-12-12 2003-07-15 The Trustees Of The University Of Pennsylvania Adaptive method and apparatus for forecasting and controlling neurological disturbances under a multi-level control
US6600954B2 (en) 2001-01-25 2003-07-29 Biocontrol Medical Bcm Ltd. Method and apparatus for selective control of nerve fibers
US8060208B2 (en) 2001-02-20 2011-11-15 Case Western Reserve University Action potential conduction prevention
US20050101878A1 (en) 2001-04-18 2005-05-12 Daly Christopher N. Method and apparatus for measurement of evoked neural response
US6658293B2 (en) 2001-04-27 2003-12-02 Medtronic, Inc. Method and system for atrial capture detection based on far-field R-wave sensing
US6816744B2 (en) 2001-05-29 2004-11-09 Reproductive Health Technologies, Inc. Device and system for remote for in-clinic trans-abdominal/vaginal/cervical acquisition, and detection, analysis, and communication of maternal uterine and maternal and fetal cardiac and fetal brain activity from electrical signals
US6936012B2 (en) 2001-06-18 2005-08-30 Neurometrix, Inc. Method and apparatus for identifying constituent signal components from a plurality of evoked physiological composite signals
EP2159723A1 (en) 2001-07-11 2010-03-03 CNS Response, Inc. Method for remote diagnosis and treatment using electroencephalografy
US6449512B1 (en) 2001-08-29 2002-09-10 Birinder R. Boveja Apparatus and method for treatment of urological disorders using programmerless implantable pulse generator system
US7778703B2 (en) 2001-08-31 2010-08-17 Bio Control Medical (B.C.M.) Ltd. Selective nerve fiber stimulation for treating heart conditions
US8571653B2 (en) 2001-08-31 2013-10-29 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation techniques
US7778711B2 (en) 2001-08-31 2010-08-17 Bio Control Medical (B.C.M.) Ltd. Reduction of heart rate variability by parasympathetic stimulation
US20140046407A1 (en) 2001-08-31 2014-02-13 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation techniques
IL145700A0 (en) 2001-09-30 2002-06-30 Younis Imad Electrode system for neural applications
DE10151020A1 (en) 2001-10-16 2003-04-30 Infineon Technologies Ag Circuit arrangement, sensor array and biosensor array
US7493157B2 (en) 2001-10-24 2009-02-17 Gozani Shai N Devices and methods for the non-invasive detection of spontaneous myoelectrical activity
US7286876B2 (en) 2001-10-26 2007-10-23 Cardiac Pacemakers, Inc. Template-based capture verification for multi-site pacing
US20050171579A1 (en) 2001-11-09 2005-08-04 Claudia Tasche Stimulating device
AUPR879201A0 (en) 2001-11-09 2001-12-06 Cochlear Limited Subthreshold stimulation of a cochlea
US7286878B2 (en) 2001-11-09 2007-10-23 Medtronic, Inc. Multiplexed electrode array extension
US6993384B2 (en) 2001-12-04 2006-01-31 Advanced Bionics Corporation Apparatus and method for determining the relative position and orientation of neurostimulation leads
US7881805B2 (en) 2002-02-04 2011-02-01 Boston Scientific Neuromodulation Corporation Method for optimizing search for spinal cord stimulation parameter settings
US20030153959A1 (en) 2002-02-12 2003-08-14 Thacker James R. Neural stimulation system providing auto adjustment of stimulus output as a function of sensed coupling efficiency
US7317948B1 (en) 2002-02-12 2008-01-08 Boston Scientific Scimed, Inc. Neural stimulation system providing auto adjustment of stimulus output as a function of sensed impedance
US6931281B2 (en) 2002-04-12 2005-08-16 Pacesetter, Inc. Method and apparatus for monitoring myocardial conduction velocity for diagnostics of therapy optimization
AU2003231354A1 (en) 2002-06-05 2003-12-22 Nervetrack Ltd. Method and apparatus for measuring nerve signals in nerve fibers
US7203548B2 (en) 2002-06-20 2007-04-10 Advanced Bionics Corporation Cavernous nerve stimulation via unidirectional propagation of action potentials
AU2003254488A1 (en) 2002-07-17 2004-02-02 Remedi (Uk) Limited Apparatus for the application of electrical pulses to the human body
AU2002951218A0 (en) 2002-09-04 2002-09-19 Cochlear Limited Method and apparatus for measurement of evoked neural response
US7328068B2 (en) 2003-03-31 2008-02-05 Medtronic, Inc. Method, system and device for treating disorders of the pelvic floor by means of electrical stimulation of the pudendal and associated nerves, and the optional delivery of drugs in association therewith
US7415307B2 (en) 2002-10-31 2008-08-19 Medtronic, Inc. Ischemia detection based on cardiac conduction time
JP2006504494A (en) 2002-11-01 2006-02-09 ジョージメイソン、インテレクチュアル、プロパティーズ、インコーポレイテッド Method and apparatus for determining brain status
US7206640B1 (en) 2002-11-08 2007-04-17 Advanced Bionics Corporation Method and system for generating a cochlear implant program using multi-electrode stimulation to elicit the electrically-evoked compound action potential
US7171261B1 (en) 2002-12-20 2007-01-30 Advanced Bionics Corporation Forward masking method for estimating neural response
US20040122482A1 (en) 2002-12-20 2004-06-24 James Tung Nerve proximity method and device
AU2004226596C1 (en) 2003-04-02 2010-09-16 Neurostream Technologies General Partnership Implantable nerve signal sensing and stimulation device for treating foot drop and other neurological disorders
DE10318071A1 (en) 2003-04-17 2004-11-25 Forschungszentrum Jülich GmbH Device for desynchronizing neuronal brain activity
US20040254494A1 (en) 2003-06-11 2004-12-16 Spokoyny Eleonora S. Method and appartaus for use in nerve conduction studies
US7582062B2 (en) 2003-09-12 2009-09-01 Medical Research Council Methods of neural centre location and electrode placement in the central nervous system
US7930037B2 (en) 2003-09-30 2011-04-19 Medtronic, Inc. Field steerable electrical stimulation paddle, lead system, and medical device incorporating the same
US8489196B2 (en) 2003-10-03 2013-07-16 Medtronic, Inc. System, apparatus and method for interacting with a targeted tissue of a patient
US7236834B2 (en) 2003-12-19 2007-06-26 Medtronic, Inc. Electrical lead body including an in-line hermetic electronic package and implantable medical device using the same
US7412287B2 (en) 2003-12-22 2008-08-12 Cardiac Pacemakers, Inc. Automatic sensing vector selection for morphology-based capture verification
US7295881B2 (en) 2003-12-29 2007-11-13 Biocontrol Medical Ltd. Nerve-branch-specific action-potential activation, inhibition, and monitoring
US20060020291A1 (en) 2004-03-09 2006-01-26 Gozani Shai N Apparatus and method for performing nerve conduction studies with multiple neuromuscular electrodes
US20050203600A1 (en) 2004-03-12 2005-09-15 Scimed Life Systems, Inc. Collapsible/expandable tubular electrode leads
GB0409806D0 (en) 2004-04-30 2004-06-09 Univ Brunel Nerve blocking method and system
US8224459B1 (en) 2004-04-30 2012-07-17 Boston Scientific Neuromodulation Corporation Insertion tool for paddle-style electrode
US7369900B2 (en) 2004-05-08 2008-05-06 Bojan Zdravkovic Neural bridge devices and methods for restoring and modulating neural activity
US8078284B2 (en) 2004-05-25 2011-12-13 Second Sight Medical Products, Inc. Retinal prosthesis with a new configuration
US7993906B2 (en) 2004-05-28 2011-08-09 The Board Of Trustees Of The Leland Stanford Junior University Closed-loop electrical stimulation system for cell cultures
US8965520B2 (en) 2004-06-15 2015-02-24 Cochlear Limited Automatic determination of the threshold of an evoked neural response
US8249698B2 (en) 2004-08-31 2012-08-21 The University Of Akron General diagnostic and real-time applications of discrete hermite functions to digital data
WO2006047291A2 (en) 2004-10-21 2006-05-04 Advanced Neuromodulation Systems, Inc. Spinal cord stimulation to treat auditory dysfunction
US8332047B2 (en) 2004-11-18 2012-12-11 Cardiac Pacemakers, Inc. System and method for closed-loop neural stimulation
US8103352B2 (en) 2004-12-03 2012-01-24 Second Sight Medical Products, Inc. Mimicking neural coding in retinal ganglion cells with short pulse electrical stimulation
US10537741B2 (en) 2004-12-03 2020-01-21 Boston Scientific Neuromodulation Corporation System and method for choosing electrodes in an implanted stimulator device
US20110307030A1 (en) 2005-03-24 2011-12-15 Michael Sasha John Methods for Evaluating and Selecting Electrode Sites of a Brain Network to Treat Brain Disorders
US7702502B2 (en) 2005-02-23 2010-04-20 Digital Intelligence, L.L.C. Apparatus for signal decomposition, analysis and reconstruction
US20070185409A1 (en) 2005-04-20 2007-08-09 Jianping Wu Method and system for determining an operable stimulus intensity for nerve conduction testing
US20060264752A1 (en) 2005-04-27 2006-11-23 The Regents Of The University Of California Electroporation controlled with real time imaging
US7818052B2 (en) 2005-06-01 2010-10-19 Advanced Bionics, Llc Methods and systems for automatically identifying whether a neural recording signal includes a neural response signal
US7343200B2 (en) 2005-06-01 2008-03-11 Advanced Bionics, Llc Methods and systems for automatically determining a neural response threshold current level
US7450992B1 (en) 2005-08-18 2008-11-11 Advanced Neuromodulation Systems, Inc. Method for controlling or regulating therapeutic nerve stimulation using electrical feedback
US8639329B2 (en) 2005-08-30 2014-01-28 Georgia Tech Research Corporation Circuits and methods for artifact elimination
US20070073354A1 (en) 2005-09-26 2007-03-29 Knudson Mark B Neural blocking therapy
US9168383B2 (en) 2005-10-14 2015-10-27 Pacesetter, Inc. Leadless cardiac pacemaker with conducted communication
US7616990B2 (en) 2005-10-24 2009-11-10 Cardiac Pacemakers, Inc. Implantable and rechargeable neural stimulator
US7957796B2 (en) 2005-10-28 2011-06-07 Cyberonics, Inc. Using physiological sensor data with an implantable medical device
US7853322B2 (en) 2005-12-02 2010-12-14 Medtronic, Inc. Closed-loop therapy adjustment
US20070287931A1 (en) 2006-02-14 2007-12-13 Dilorenzo Daniel J Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders
US7894905B2 (en) 2006-03-13 2011-02-22 Neuropace, Inc. Implantable system enabling responsive therapy for pain
US7689289B2 (en) 2006-03-22 2010-03-30 Medtronic, Inc. Technique for adjusting the locus of excitation of electrically excitable tissue with paired pulses
US8190251B2 (en) 2006-03-24 2012-05-29 Medtronic, Inc. Method and apparatus for the treatment of movement disorders
US7835804B2 (en) 2006-04-18 2010-11-16 Advanced Bionics, Llc Removing artifact in evoked compound action potential recordings in neural stimulators
DE102006018851A1 (en) 2006-04-22 2007-10-25 Biotronik Crm Patent Ag Active medical device implant with at least two diagnostic and / or therapeutic functions
US7792584B2 (en) 2006-04-25 2010-09-07 Medtronic, Inc. System and method for characterization of atrial wall using digital signal processing
US8099172B2 (en) 2006-04-28 2012-01-17 Advanced Neuromodulation Systems, Inc. Spinal cord stimulation paddle lead and method of making the same
US9084901B2 (en) 2006-04-28 2015-07-21 Medtronic, Inc. Cranial implant
US7515968B2 (en) 2006-04-28 2009-04-07 Medtronic, Inc. Assembly method for spinal cord stimulation lead
US20080051647A1 (en) 2006-05-11 2008-02-28 Changwang Wu Non-invasive acquisition of large nerve action potentials (NAPs) with closely spaced surface electrodes and reduced stimulus artifacts
US20070282217A1 (en) 2006-06-01 2007-12-06 Mcginnis William J Methods & systems for intraoperatively monitoring nerve & muscle frequency latency and amplitude
WO2008004204A1 (en) * 2006-07-06 2008-01-10 University Of Limerick An electrical stimulation device for nerves or muscles
US8532741B2 (en) 2006-09-08 2013-09-10 Medtronic, Inc. Method and apparatus to optimize electrode placement for neurological stimulation
US9162051B2 (en) 2006-09-21 2015-10-20 Neuropace, Inc. Treatment of language, behavior and social disorders
EP2069011B1 (en) 2006-10-06 2013-11-20 Neurostream Technologies General Partnership Implantable pulse generator
US7881803B2 (en) 2006-10-18 2011-02-01 Boston Scientific Neuromodulation Corporation Multi-electrode implantable stimulator device with a single current path decoupling capacitor
US8280514B2 (en) 2006-10-31 2012-10-02 Advanced Neuromodulation Systems, Inc. Identifying areas of the brain by examining the neuronal signals
US8160719B2 (en) 2006-12-19 2012-04-17 Greatbatch Ltd. Braided electrical lead
US8057390B2 (en) 2007-01-26 2011-11-15 The Regents Of The University Of Michigan High-resolution mapping of bio-electric fields
US8224453B2 (en) 2007-03-15 2012-07-17 Advanced Neuromodulation Systems, Inc. Spinal cord stimulation to treat pain
US8406877B2 (en) 2007-03-19 2013-03-26 Cardiac Pacemakers, Inc. Selective nerve stimulation with optionally closed-loop capabilities
US8083685B2 (en) 2007-05-08 2011-12-27 Propep, Llc System and method for laparoscopic nerve detection
US9042978B2 (en) 2007-05-11 2015-05-26 Neurometrix, Inc. Method and apparatus for quantitative nerve localization
US7742810B2 (en) 2007-05-23 2010-06-22 Boston Scientific Neuromodulation Corporation Short duration pre-pulsing to reduce stimulation-evoked side-effects
US7634315B2 (en) 2007-05-31 2009-12-15 Pacesetter, Inc. Techniques to monitor and trend nerve damage and recovery
KR100897528B1 (en) 2007-06-22 2009-05-15 주식회사 사이버메드 Method of determining the position of a deep brain stimulation electrode
US8649858B2 (en) 2007-06-25 2014-02-11 Boston Scientific Neuromodulation Corporation Architectures for an implantable medical device system
US8417342B1 (en) 2007-07-03 2013-04-09 University Of Mississippi Medical Center Gastrointestinal electrical stimulation device and method for treating gastrointestinal disorders
US8391993B2 (en) 2007-07-13 2013-03-05 Cochlear Limited Using interaction to measure neural excitation
US8063770B2 (en) 2007-08-01 2011-11-22 Peter Costantino System and method for facial nerve monitoring
WO2009026625A1 (en) 2007-08-29 2009-03-05 Cochlear Limited Method and device for intracochlea impedance measurement
US7978062B2 (en) 2007-08-31 2011-07-12 Cardiac Pacemakers, Inc. Medical data transport over wireless life critical network
WO2009042172A2 (en) 2007-09-26 2009-04-02 Medtronic, Inc. Frequency selective monitoring of physiological signals
US9248274B2 (en) 2007-10-10 2016-02-02 Sorin Crm Sas Neurostimulator and method for regulating same
DE102007051847B4 (en) 2007-10-30 2014-07-17 Forschungszentrum Jülich GmbH Device for stimulating neurons with a pathologically synchronous and oscillatory neuronal activity
EP2217323B1 (en) 2007-11-14 2017-02-01 Med-El Elektromedizinische Geräte GmbH Cochlear implant stimulation artifacts
US8195287B2 (en) 2007-12-05 2012-06-05 The Invention Science Fund I, Llc Method for electrical modulation of neural conduction
US20090157155A1 (en) 2007-12-18 2009-06-18 Advanced Bionics Corporation Graphical display of environmental measurements for implantable therapies
GB0800797D0 (en) 2008-01-16 2008-02-27 Cambridge Entpr Ltd Neural interface
WO2009119236A1 (en) 2008-03-26 2009-10-01 テルモ株式会社 Treatment apparatus
US8401213B2 (en) 2008-03-31 2013-03-19 Cochlear Limited Snap-lock coupling system for a prosthetic device
GR1006568B (en) 2008-04-22 2009-10-13 Αλεξανδρος Μπερης Method and system for recording of, and aiding in, the regeneration of a peripheral nerve.
US9492655B2 (en) 2008-04-25 2016-11-15 Boston Scientific Neuromodulation Corporation Stimulation system with percutaneously deliverable paddle lead and methods of making and using
WO2009134478A1 (en) 2008-04-29 2009-11-05 Medtronic, Inc. Therapy program modification
US8315703B2 (en) 2008-04-30 2012-11-20 Advanced Neuromodulation Systems, Inc. Methods for targeting deep brain sites to treat mood and/or anxiety disorders
US8805518B2 (en) 2008-05-09 2014-08-12 Medtronic, Inc. Peripheral nerve field stimulation control
US7890182B2 (en) 2008-05-15 2011-02-15 Boston Scientific Neuromodulation Corporation Current steering for an implantable stimulator device involving fractionalized stimulation pulses
US20090287277A1 (en) 2008-05-19 2009-11-19 Otologics, Llc Implantable neurostimulation electrode interface
WO2009146427A1 (en) 2008-05-29 2009-12-03 Neurometrix, Inc. Method and apparatus for quantitative nerve localization
WO2009143553A1 (en) 2008-05-30 2009-12-03 Cochlear Limited Sound processing method and system
US20090306491A1 (en) 2008-05-30 2009-12-10 Marcus Haggers Implantable neural prosthetic device and methods of use
US8515550B2 (en) 2008-07-11 2013-08-20 Medtronic, Inc. Assignment of therapy parameter to multiple posture states
US8249718B2 (en) 2008-07-11 2012-08-21 Medtronic, Inc. Programming posture state-responsive therapy with nominal therapy parameters
JP5479473B2 (en) 2008-07-29 2014-04-23 コーニンクレッカ フィリップス エヌ ヴェ System and method for communicating information between embedded devices
US7941713B2 (en) 2008-08-27 2011-05-10 Taiwan Semiconductor Manufacturing Company, Ltd. Programmable self-test for random access memories
US8897888B2 (en) 2008-09-17 2014-11-25 Saluda Medical Pty Limited Knitted electrode assembly and integrated connector for an active implantable medical device
WO2010032132A1 (en) 2008-09-17 2010-03-25 Med-El Elektromedizinische Geraete Gmbh Stimulus artifact removal for neuronal recordings
US8428733B2 (en) 2008-10-16 2013-04-23 Medtronic, Inc. Stimulation electrode selection
US20110204811A1 (en) 2008-10-27 2011-08-25 Koninklijke Philips Electronics N.V. Method of driving a short-arc discharge lamp
US9987493B2 (en) 2008-10-28 2018-06-05 Medtronic, Inc. Medical devices and methods for delivery of current-based electrical stimulation therapy
US8688210B2 (en) 2008-10-31 2014-04-01 Medtronic, Inc. Implantable medical device crosstalk evaluation and mitigation
US8560060B2 (en) 2008-10-31 2013-10-15 Medtronic, Inc. Isolation of sensing and stimulation circuitry
US8301263B2 (en) 2008-10-31 2012-10-30 Medtronic, Inc. Therapy module crosstalk mitigation
WO2010051382A1 (en) 2008-10-31 2010-05-06 Medtronic, Inc. Mood circuit monitoring to control therapy delivery
US8255057B2 (en) 2009-01-29 2012-08-28 Nevro Corporation Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions
WO2010057046A2 (en) 2008-11-13 2010-05-20 Proteus Biomedical, Inc. Multiplexed multi-electrode neurostimulation devices
US9463321B2 (en) 2008-11-14 2016-10-11 Boston Scientific Neuromodulation Corporation System and method for adjusting automatic pulse parameters to selectively activate nerve fibers
US8504160B2 (en) 2008-11-14 2013-08-06 Boston Scientific Neuromodulation Corporation System and method for modulating action potential propagation during spinal cord stimulation
AU2009322898B2 (en) 2008-12-05 2015-03-12 Spr Therapeutics, Inc. Systems and methods to place one or more leads in tissue to electrically stimulate nerves of passage to treat pain
US9084551B2 (en) 2008-12-08 2015-07-21 Medtronic Xomed, Inc. Method and system for monitoring a nerve
US20100179626A1 (en) 2009-01-09 2010-07-15 Medtronic, Inc. System and method for implanting a paddle lead
US20100222858A1 (en) 2009-02-27 2010-09-02 Meloy T Stuart Method and system for neurally augmenting sexual function during sexual activity
EP2405823A4 (en) 2009-03-13 2012-07-04 Baxano Inc Flexible neural localization devices and methods
US10252074B2 (en) 2009-03-20 2019-04-09 ElectroCore, LLC Nerve stimulation methods for averting imminent onset or episode of a disease
US10286212B2 (en) 2009-03-20 2019-05-14 Electrocore, Inc. Nerve stimulation methods for averting imminent onset or episode of a disease
US8504154B2 (en) 2009-03-30 2013-08-06 Medtronic, Inc. Physiological signal amplifier with voltage protection and fast signal recovery
AU2009344196A1 (en) 2009-04-08 2011-12-01 Saluda Medical Pty Limited Electronics package for an active implantable medical device
AU2009344197A1 (en) 2009-04-08 2011-12-01 Saluda Medical Pty Limited Bonded hermetic feed through for an active implantable medical device
JP2012523268A (en) 2009-04-08 2012-10-04 ナショナル・アイシーティ・オーストラリア・リミテッド Sewing components for implantable medical devices
ES2624748T3 (en) 2009-04-22 2017-07-17 Nevro Corporation Selective high frequency modulation of the spinal cord for pain inhibition with reduced side effects, and associated systems and methods
US8744588B2 (en) 2009-05-07 2014-06-03 Hani Midani Method and system for connecting an impaired nervous system to a muscle or a group of muscles based on template matching and intelligent end points
US20120226187A1 (en) 2009-05-29 2012-09-06 University of Washington Center for Commercialization Vestibular Implant
US20100331926A1 (en) 2009-06-24 2010-12-30 Boston Scientific Neuromodulation Corporation Reversing recruitment order by anode intensification
EP2456515A4 (en) 2009-07-20 2013-01-23 Nat Ict Australia Ltd Neuro-stimulation
US8498710B2 (en) 2009-07-28 2013-07-30 Nevro Corporation Linked area parameter adjustment for spinal cord stimulation and associated systems and methods
US20110028859A1 (en) 2009-07-31 2011-02-03 Neuropace, Inc. Methods, Systems and Devices for Monitoring a Target in a Neural System and Facilitating or Controlling a Cell Therapy
EP2464283A4 (en) 2009-08-14 2017-10-25 David Burton Anaesthesia and consciousness depth monitoring system
US20110093042A1 (en) 2009-10-21 2011-04-21 Medtronic, Inc. Stimulation with utilization of case electrode
WO2011119251A2 (en) 2010-03-22 2011-09-29 Research Foundation Of The City University Of New York Charge-enhanced neural electric stimulation system
US11045221B2 (en) 2009-10-30 2021-06-29 Medtronic, Inc. Steerable percutaneous paddle stimulation lead
WO2011066477A1 (en) 2009-11-26 2011-06-03 National Ict Australia Limited (Nicta) Methods for forming feedthroughs for hermetically sealed housings using powder injection molding
US8886323B2 (en) 2010-02-05 2014-11-11 Medtronic, Inc. Electrical brain stimulation in gamma band
CA2792529C (en) 2010-03-11 2018-06-05 Mainstay Medical, Inc. Modular stimulator for treatment of back pain, implantable rf ablation system and methods of use
EP2544590B1 (en) 2010-03-12 2018-02-14 Inspire Medical Systems, Inc. System for identifying a location for nerve stimulation
US9814885B2 (en) 2010-04-27 2017-11-14 Medtronic, Inc. Stimulation electrode selection
US8888699B2 (en) 2010-04-29 2014-11-18 Medtronic, Inc. Therapy using perturbation and effect of physiological systems
JP5464072B2 (en) 2010-06-16 2014-04-09 ソニー株式会社 Muscle activity diagnosis apparatus and method, and program
AU2013277009B2 (en) 2010-06-18 2016-01-07 Cardiac Pacemakers, Inc. Neurostimulation system with control using evoked responses
US8972022B2 (en) 2010-06-18 2015-03-03 Cardiac Pacemakers, Inc. Methods and apparatus for controlling neurostimulation using evoked responses
EP3485808A1 (en) 2010-07-29 2019-05-22 MED-EL Elektromedizinische Geräte GmbH Electrically evoked brainstem response measurements via implant prosthesis
EP2608845A2 (en) 2010-08-23 2013-07-03 Rafael Development Corporation Ltd. Synchronizing defibrillation pulse delivery with the breathing cycle
WO2012027791A1 (en) 2010-08-31 2012-03-08 National Ict Australia Ltd Distributed implant systems
US9420960B2 (en) 2010-10-21 2016-08-23 Medtronic, Inc. Stereo data representation of biomedical signals along a lead
EP2443995A3 (en) * 2010-10-21 2013-02-27 Syncrophi Systems Ltd. An ECG apparatus with lead-off detection
US8805697B2 (en) 2010-10-25 2014-08-12 Qualcomm Incorporated Decomposition of music signals using basis functions with time-evolution information
WO2012056882A1 (en) 2010-10-27 2012-05-03 株式会社村田製作所 Detection circuit
US9155503B2 (en) 2010-10-27 2015-10-13 Cadwell Labs Apparatus, system, and method for mapping the location of a nerve
US8788047B2 (en) 2010-11-11 2014-07-22 Spr Therapeutics, Llc Systems and methods for the treatment of pain through neural fiber stimulation
KR101198515B1 (en) 2010-12-15 2012-11-06 에스케이하이닉스 주식회사 Operating method of semiconductor memory device
US9326698B2 (en) 2011-02-18 2016-05-03 The Trustees Of The University Of Pennsylvania Method for automatic, unsupervised classification of high-frequency oscillations in physiological recordings
KR101241943B1 (en) 2011-03-29 2013-03-11 한국과학기술연구원 Artificial Nerve Networking System and Method for Functional Recovery of Damaged Nerve
US9155879B2 (en) 2011-04-08 2015-10-13 University Of Utah Research Foundation Virtual electrodes for high-density electrode arrays
US9789307B2 (en) 2011-04-29 2017-10-17 Medtronic, Inc. Dual prophylactic and abortive electrical stimulation
US10448889B2 (en) 2011-04-29 2019-10-22 Medtronic, Inc. Determining nerve location relative to electrodes
US8515545B2 (en) 2011-04-29 2013-08-20 Greatbatch Ltd. Current steering neurostimulator device with unidirectional current sources
AU2012255671B2 (en) 2011-05-13 2016-10-06 Saluda Medical Pty Limited Method and apparatus for measurement of neural response - a
US10568559B2 (en) 2011-05-13 2020-02-25 Saluda Medical Pty Ltd Method and apparatus for measurement of neural response
US9872990B2 (en) 2011-05-13 2018-01-23 Saluda Medical Pty Limited Method and apparatus for application of a neural stimulus
WO2012155189A1 (en) 2011-05-13 2012-11-22 National Ict Australia Ltd Method and apparatus for estimating neural recruitment - f
US10588524B2 (en) 2011-05-13 2020-03-17 Saluda Medical Pty Ltd Method and apparatus for measurement of neural response
WO2012155187A1 (en) 2011-05-13 2012-11-22 National Ict Australia Ltd Method and apparatus for application of a neural stimulus - i
DK3357533T3 (en) 2011-05-13 2021-11-15 Saluda Medical Pty Ltd DEVICE FOR CONTROLLING A NEURAL STIMULUS
AU2012258886B2 (en) 2011-05-24 2015-06-11 Med-El Elektromedizinische Geraete Gmbh Progressive parameter scan for cochlear implants
US20130172774A1 (en) 2011-07-01 2013-07-04 Neuropace, Inc. Systems and Methods for Assessing the Effectiveness of a Therapy Including a Drug Regimen Using an Implantable Medical Device
EP2739345A4 (en) 2011-08-04 2015-04-15 Univ Ramot Il-1 receptor antagonist-coated electrode and uses thereof
US9888861B2 (en) 2011-08-25 2018-02-13 Medtronic, Inc. Method and apparatus for detecting a biomarker in the presence of electrical stimulation
US8483836B2 (en) 2011-09-07 2013-07-09 Greatbatch Ltd. Automated search to identify a location for electrical stimulation to treat a patient
WO2013063111A1 (en) 2011-10-24 2013-05-02 Purdue Research Foundation Method and apparatus for closed-loop control of nerve activation
US20140288577A1 (en) 2011-11-24 2014-09-25 Saluda Medical Pty Limited Electrode Assembly for an Active Implantable Medical Device
WO2013116161A1 (en) 2012-01-30 2013-08-08 The Regents Of The University Of California System and methods for closed-loop cochlear implant
FR2988996B1 (en) 2012-04-06 2015-01-23 Uromems METHOD AND DEVICE FOR CONTROLLING AN IMPLANTABLE DEVICE
WO2013162793A1 (en) 2012-04-27 2013-10-31 Boston Scientific Neuromodulation Timing channel circuitry for creating pulses in an implantable stimulator device
EP2849839A4 (en) 2012-05-16 2015-12-09 Univ Utah Res Found Charge steering high density electrode array
AU2013273952B2 (en) 2012-06-15 2017-02-23 Case Western Reserve University Implantable cuff and method for functional electrical stimulation and monitoring
CN104411360B (en) 2012-06-21 2017-06-27 神经毫微股份公司 Medical microelectrode, its manufacture method and its use
TWI498101B (en) 2012-08-30 2015-09-01 Univ Nat Chiao Tung Method of analyzing nerve fiber distribution and measuring standardized induced compound motion electric potential
DE102012218057A1 (en) 2012-10-02 2014-04-03 Forschungszentrum Jülich GmbH DEVICE AND METHOD FOR INVESTIGATING A NARROW INTERACTION BETWEEN DIFFERENT BRAIN SIZES
US20150282725A1 (en) 2012-11-06 2015-10-08 Saluda Medical Pty Ltd Method and System for Controlling Electrical Conditions of Tissue II
DK2908904T3 (en) 2012-11-06 2020-12-14 Saluda Medical Pty Ltd SYSTEM FOR CONTROLING THE ELECTRICAL CONDITION OF TISSUE
US8880167B2 (en) 2013-02-13 2014-11-04 Flint Hills Scientific, Llc Selective recruitment and activation of fiber types in nerves for the control of undesirable brain state changes
US9533148B2 (en) 2013-02-22 2017-01-03 Boston Scientific Neuromodulation Corporation Neurostimulation system and method for automatically adjusting stimulation and reducing energy requirements using evoked action potential
US20140276925A1 (en) 2013-03-12 2014-09-18 Spinal Modulation, Inc. Methods and systems for use in guiding implantation of a neuromodulation lead
US10105091B2 (en) 2013-03-12 2018-10-23 The Cleveland Clinic Foundation Methods of using nerve evoked potentials to monitor a surgical procedure
US9446235B2 (en) 2013-03-14 2016-09-20 Medtronic, Inc. Low frequency electrical stimulation therapy for pelvic floor disorders
US20140277267A1 (en) 2013-03-15 2014-09-18 Boston Scientific Neuromodulation Corporation Neuromodulation system and method for transitioning between programming modes
US9610444B2 (en) 2013-03-15 2017-04-04 Pacesetter, Inc. Erythropoeitin production by electrical stimulation
EP2968949B1 (en) 2013-03-15 2019-12-25 Boston Scientific Neuromodulation Corporation Techniques for current steering directional programming in a neurostimulation system
US9427581B2 (en) 2013-04-28 2016-08-30 ElectroCore, LLC Devices and methods for treating medical disorders with evoked potentials and vagus nerve stimulation
US20140350634A1 (en) 2013-05-21 2014-11-27 Duke University Devices, systems and methods for deep brain stimulation parameters
US11083402B2 (en) 2013-06-04 2021-08-10 Medtronic, Inc. Patient state determination based on one or more spectral characteristics of a bioelectrical brain signal
US9545516B2 (en) 2013-07-19 2017-01-17 Med-El Elektromedizinische Geraete Gmbh Triphasic pulses to reduce undesirable side-effects in cochlear implants
EP3777963B1 (en) 2013-07-19 2023-08-30 MED-EL Elektromedizinische Geräte GmbH Triphasic pulses to reduce undesirable side-effects in cochlear implants
JP6538673B2 (en) 2013-11-01 2019-07-03 メドトロニック・ゾーメド・インコーポレーテッド Foley catheter with ring electrode
AU2014351064B2 (en) 2013-11-15 2019-07-04 Closed Loop Medical Pty Ltd Monitoring brain neural potentials
WO2015074121A1 (en) 2013-11-22 2015-05-28 Saluda Medical Pty Ltd Method and device for detecting a neural response in a neural measurement
WO2015109239A1 (en) 2014-01-17 2015-07-23 Medtronic, Inc. Movement disorder symptom control
WO2015143509A1 (en) 2014-03-28 2015-10-01 Saluda Medical Pty Ltd Assessing neural state from action potentials
CA2944042C (en) 2014-05-05 2023-08-29 Saluda Medical Pty Ltd Improved neural measurement
US9302112B2 (en) 2014-06-13 2016-04-05 Pacesetter, Inc. Method and system for non-linear feedback control of spinal cord stimulation
EP3171929B1 (en) 2014-07-25 2021-03-24 Saluda Medical Pty Limited Neural stimulation dosing
US9814880B2 (en) 2014-09-23 2017-11-14 Boston Scientific Neuromodulation Corporation Short pulse width stimulation
AU2015321576B2 (en) 2014-09-23 2018-11-08 Boston Scientific Neuromodulation Corporation Systems and methods for receiving user-provided selection of electrode lists
CN106714897B (en) 2014-09-23 2020-02-07 波士顿科学神经调制公司 System for calibrating dorsal horn stimulation
US10130817B2 (en) 2014-10-13 2018-11-20 Cardiac Pacemakers, Inc. Systems and methods for delivering vagal therapy
US10471268B2 (en) 2014-10-16 2019-11-12 Mainstay Medical Limited Systems and methods for monitoring muscle rehabilitation
US9597507B2 (en) 2014-10-31 2017-03-21 Medtronic, Inc. Paired stimulation pulses based on sensed compound action potential
US9610448B2 (en) 2014-11-12 2017-04-04 Pacesetter, Inc. System and method to control a non-paresthesia stimulation based on sensory action potentials
US11006846B2 (en) 2014-11-17 2021-05-18 Saluda Medical Pty Ltd Method and device for detecting a neural response in neural measurements
US10603484B2 (en) 2014-11-25 2020-03-31 Medtronic Bakken Research Center B.V. System and method for neurostimulation and/or neurorecording
US20160166164A1 (en) 2014-12-11 2016-06-16 Saluda Medical Pty Limited Method and Apparatus for Detecting Neural Injury
AU2015362075B2 (en) 2014-12-11 2021-03-11 Saluda Medical Pty Ltd Implantable electrode positioning
WO2016090436A1 (en) 2014-12-11 2016-06-16 Saluda Medical Pty Ltd Method and device for feedback control of neural stimulation
US9387325B1 (en) 2014-12-19 2016-07-12 Pacesetter, Inc. System and method to control dorsal root stimulation parameters based on frequency decomposition
US10918872B2 (en) 2015-01-19 2021-02-16 Saluda Medical Pty Ltd Method and device for neural implant communication
JP7071121B2 (en) 2015-04-09 2022-05-18 サルーダ・メディカル・ピーティーワイ・リミテッド Estimating the distance between the electrode and the nerve
EP3283166A4 (en) 2015-04-17 2019-01-16 Micron Devices LLC Flexible circuit for an impantable device
CN107613860B (en) 2015-05-31 2022-01-11 闭环医疗私人有限公司 Cranial nerve activity monitoring
AU2016269837B2 (en) 2015-05-31 2021-10-21 Closed Loop Medical Pty Ltd Brain neurostimulator electrode fitting
WO2016191815A1 (en) 2015-06-01 2016-12-08 Saluda Medical Pty Ltd Motor fibre neuromodulation
WO2017053504A1 (en) 2015-09-22 2017-03-30 Cardiac Pacemakers, Inc. Systems and methods for monitoring autonomic health
CN108367153A (en) 2015-12-04 2018-08-03 波士顿科学神经调制公司 System and method for sharing treatment example in neural modulation system
EP3184145B1 (en) 2015-12-22 2024-03-20 Ecole Polytechnique Fédérale de Lausanne (EPFL) System for selective spatiotemporal stimulation of the spinal cord
US9925379B2 (en) 2015-12-22 2018-03-27 Pacesetter, Inc. System and method for managing stimulation of select A-beta fiber components
AU2017221321B2 (en) 2016-02-19 2021-04-15 Nalu Medical, Inc. Apparatus with enhanced stimulation waveforms
CA3019701A1 (en) 2016-04-05 2017-10-12 Saluda Medical Pty Ltd Improved feedback control of neuromodulation
AU2017273638A1 (en) 2016-05-31 2018-12-06 The Regents Of The University Of California Systems and methods for reducing noise caused by stimulation artifacts in neural signals received by neuro-modulation devices
WO2017219096A1 (en) 2016-06-24 2017-12-28 Saluda Medical Pty Ltd Neural stimulation for reduced artefact
US10576265B2 (en) 2016-09-10 2020-03-03 Boston Scientific Neuromodulation Corporation Pulse definition circuitry for creating stimulation waveforms in an implantable pulse generator
US20180104493A1 (en) 2016-10-19 2018-04-19 Boston Scientific Neuromodulation Corporation Methods to program sub-perception spinal cord stimulation
EP3532151A1 (en) 2016-10-28 2019-09-04 Medtronic, Inc. Controlling electrical stimulation therapy
US11351378B2 (en) 2016-12-21 2022-06-07 Duke University Method to design temporal patterns of nervous system stimulation
US11759146B2 (en) 2017-03-02 2023-09-19 Cornell University Sensory evoked diagnostic for the assessment of cognitive brain function
EP3595769A4 (en) 2017-03-15 2021-05-26 The Regents of the University of California Removal of stimulation artifact in multi-channel neural recordings
EP3434321A1 (en) 2017-07-26 2019-01-30 BIOTRONIK SE & Co. KG Neural stimulation and recording, particularly for neuromodulation closed-loop control
AU2018414327A1 (en) 2018-03-23 2020-10-01 Saluda Medical Pty Ltd System for managing clinical data
US11944820B2 (en) 2018-04-27 2024-04-02 Saluda Medical Pty Ltd Neurostimulation of mixed nerves
WO2019231796A1 (en) 2018-06-01 2019-12-05 Boston Scientific Neuromodulation Corporation Artifact reduction in a sensed neural response
CN113226451A (en) 2018-10-23 2021-08-06 萨鲁达医疗有限公司 Nerve stimulation artifact minimization
CA3117230A1 (en) 2018-10-23 2020-04-30 Saluda Medical Pty Ltd Method and device for controlled neural stimulation
WO2020082128A1 (en) 2018-10-23 2020-04-30 Saluda Medical Pty Ltd Current source for neurostimulation
WO2020087123A1 (en) 2018-10-30 2020-05-07 Saluda Medical Pty Ltd Automated neural conduction velocity estimation
EP3873335A4 (en) 2018-11-02 2022-07-27 Saluda Medical Pty Ltd Characterisation of neurostimulation therapeutic efficacy
AU2019408264A1 (en) 2018-12-17 2021-06-17 Saluda Medical Pty Ltd Improved detection of action potentials

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11045129B2 (en) 2011-05-13 2021-06-29 Saluda Medical Pty Ltd. Method and apparatus for estimating neural recruitment
US11491334B2 (en) 2011-05-13 2022-11-08 Saluda Medical Pty Ltd Method and apparatus for application of a neural stimulus
US11944440B2 (en) 2011-05-13 2024-04-02 Saluda Medical Pty Ltd Method and apparatus for estimating neural recruitment
US11324427B2 (en) 2011-05-13 2022-05-10 Saluda Medical Pty Ltd Method and apparatus for measurement of neural response
US10568559B2 (en) 2011-05-13 2020-02-25 Saluda Medical Pty Ltd Method and apparatus for measurement of neural response
US11554265B2 (en) 2011-05-13 2023-01-17 Saluda Medical Pty Ltd Method and apparatus for application of a neural stimulus
US10588524B2 (en) 2011-05-13 2020-03-17 Saluda Medical Pty Ltd Method and apparatus for measurement of neural response
US11464979B2 (en) 2011-05-13 2022-10-11 Saluda Medical Pty Ltd Method and apparatus for application of a neural stimulus
US11819332B2 (en) 2011-05-13 2023-11-21 Saluda Medical Pty Ltd Method and apparatus for measurement of neural response
US11445958B2 (en) 2011-05-13 2022-09-20 Saluda Medical Pty Ltd Method and apparatus for estimating neural recruitment
US11439828B2 (en) 2011-05-13 2022-09-13 Saluda Medical Pty Ltd Method and apparatus for application of a neural stimulus
US11413460B2 (en) 2011-05-13 2022-08-16 Saluda Medical Pty Ltd Method and apparatus for application of a neural stimulus
US11426587B2 (en) 2011-05-13 2022-08-30 Saluda Medical Pty Ltd Method and apparatus for application of a neural stimulus
US11420064B2 (en) 2011-05-13 2022-08-23 Saluda Medical Pty Ltd Method and apparatus for application of a neural stimulus
US11944439B2 (en) 2012-11-06 2024-04-02 Saluda Medical Pty Ltd Method and system for controlling electrical conditions of tissue
US11172864B2 (en) 2013-11-15 2021-11-16 Closed Loop Medical Pty Ltd Monitoring brain neural potentials
US11337658B2 (en) 2013-11-22 2022-05-24 Saluda Medical Pty Ltd Method and device for detecting a neural response in a neural measurement
US11890113B2 (en) 2013-11-22 2024-02-06 Saluda Medical Pty Ltd Method and device for detecting a neural response in a neural measurement
US11457849B2 (en) 2014-05-05 2022-10-04 Saluda Medical Pty Ltd Neural measurement
US11167129B2 (en) 2014-07-25 2021-11-09 Saluda Medical Pty Ltd Neural stimulation dosing
US10632307B2 (en) 2014-07-25 2020-04-28 Saluda Medical Pty Ltd Neural stimulation dosing
US11006846B2 (en) 2014-11-17 2021-05-18 Saluda Medical Pty Ltd Method and device for detecting a neural response in neural measurements
US11219766B2 (en) 2014-12-11 2022-01-11 Saluda Medical Pty Ltd Method and device for feedback control of neural stimulation
US10588698B2 (en) 2014-12-11 2020-03-17 Saluda Medical Pty Ltd Implantable electrode positioning
US11464980B2 (en) 2014-12-11 2022-10-11 Saluda Medical Pty Ltd Method and device for feedback control of neural stimulation
US11344729B1 (en) 2014-12-11 2022-05-31 Saluda Medical Pty Ltd Method and device for feedback control of neural stimulation
US11938320B2 (en) 2015-04-09 2024-03-26 Saluda Medical Pty Ltd Electrode to nerve distance estimation
US10894158B2 (en) 2015-04-09 2021-01-19 Saluda Medical Pty Ltd Electrode to nerve distance estimation
US10849525B2 (en) 2015-05-31 2020-12-01 Saluda Medical Pty Ltd Monitoring brain neural activity
US11110270B2 (en) 2015-05-31 2021-09-07 Closed Loop Medical Pty Ltd Brain neurostimulator electrode fitting
US11006857B2 (en) 2015-06-01 2021-05-18 Closed Loop Medical Pty Ltd Motor fibre neuromodulation
US11191966B2 (en) 2016-04-05 2021-12-07 Saluda Medical Pty Ltd Feedback control of neuromodulation
US11826156B2 (en) 2016-06-24 2023-11-28 Saluda Medical Pty Ltd Neural stimulation for reduced artefact
US11179091B2 (en) 2016-06-24 2021-11-23 Saluda Medical Pty Ltd Neural stimulation for reduced artefact
US11944820B2 (en) 2018-04-27 2024-04-02 Saluda Medical Pty Ltd Neurostimulation of mixed nerves

Also Published As

Publication number Publication date
DK2908904T3 (en) 2020-12-14
AU2013344311B2 (en) 2017-11-30
ES2834958T8 (en) 2021-12-28
ES2834958T3 (en) 2021-06-21
US20220354406A1 (en) 2022-11-10
AU2013344311A1 (en) 2015-04-23
EP2908904A1 (en) 2015-08-26
WO2014071445A1 (en) 2014-05-15
US20150313487A1 (en) 2015-11-05
US10206596B2 (en) 2019-02-19
US11389098B2 (en) 2022-07-19
EP2908904B1 (en) 2020-09-23
US11944439B2 (en) 2024-04-02
EP2908904A4 (en) 2016-07-20

Similar Documents

Publication Publication Date Title
US11944439B2 (en) Method and system for controlling electrical conditions of tissue
US20220007980A1 (en) Method and System for Controlling Electrical Conditions of Tissue II
US11324427B2 (en) Method and apparatus for measurement of neural response
US11944440B2 (en) Method and apparatus for estimating neural recruitment
AU2017280112B2 (en) Neural stimulation for reduced artefact
US20210393964A1 (en) Neurostimulation Artefact Minimisation
EP4153055A1 (en) Neural recording with stimulus crosstalk compensation

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

AS Assignment

Owner name: NATIONAL ICT AUSTRALIA LTD, AUSTRALIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SINGLE, PETER SCOTT VALLACK;WAH, JAMES HAMILTON;REEL/FRAME:052956/0912

Effective date: 20160504

Owner name: SALUDA MEDICAL PTY LTD, AUSTRALIA

Free format text: CONFIRMATION OF ASSIGNMENT;ASSIGNOR:NICTA IPR PTY LTD;REEL/FRAME:052958/0202

Effective date: 20130117

Owner name: NICTA IPR PTY LTD, AUSTRALIA

Free format text: CONFIRMATION OF ASSIGNMENT;ASSIGNOR:NATIONAL ICT AUSTRALIA LTD;REEL/FRAME:052958/0180

Effective date: 20130117

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE